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1.1 SOMMARIO 
Recenti evidenze sperimentali su modelli murini indicano che la leucemia mieloide 
acuta (LMA) è contraddistinta dalla presenza di una popolazione cellulare definita 
come Leukemia Initiating Cells (LICs), la quale è in grado di autorigenerarsi dando 
inizio e sostenendo la LMA. Una questione tuttora dibattuta riguarda l’esclusiva 
presenza delle LICs in una ristretta popolazione cellulare definita dai marcatori 
CD34+CD38- e nuove evidenze sperimentali suggeriscono che una più ampia 
eterogeneità della componente cellulare caratterizzante le LICs sia contenuta nella 
suddetta popolazione. Uno dei marcatori più efficaci ai fini dell’arricchimento della 
popolazione staminale è l’antigene AC133, che definisce una popolazione cellulare 
di progenitori e cellule staminali identificate sia nella frazione cellulare 
CD34brightCD38- che nella frazione CD34brightCD38+. L’AC133 è stato utilizzato, per 
la definizione della cancer stem cell (CSC) in grado di sostenere il tumore in altri 
contesti neoplastici rispetto alla LMA, quali tumori cerebrali umani e la leucemia 
linfoblastica acuta infantile. In recenti studi su modelli murini è emerso che il 
pathway WNT/β-catenine interpreta un ruolo importante nel processo patogenetico 
della LMA. Nonostante ciò, la relazione tra il WNT/β-catenine signaling e i 
programmi trascrizionali che sostengono l’autorinnovamento cellulare resta ancora 
poco chiara. A tal proposito è nata la necessità di identificare i programmi 
trascrizionali coinvolti nel mantenimento dello stato autorinnovativo delle LSCs. 
Considerando il ruolo di alcuni TFs nella riprogrammazione cellulare, abbiamo 
generato un dataset di regolatori trascrizionali (TRs) con l’obiettivo di interrogare i 
dati di espressione ottenuti mediante microarrays su frazioni cellulari AC133+ in 
una casistica di 33 pazienti con diagnosi di LMA e da 10 donatori sani. L’analisi 
multistep dei dati generati, ha evidenziato il coinvolgimento del pathway 
rigenerativo WNT-dipendente, come la funzione cellulare più significativamente 
deregolata nelle frazioni cellulari, arricchite per l’AC133, in pazienti affetti da LMA. 
L’obiettivo di questo studio è volto alla caratterizzazione dell’attivazione del Wnt 
pathway associato al contesto rigenerativo nella LMA. I nostri dati suggeriscono 
che il signaling canonico WNT/β-catenine è attivato nella frazione leucemica 
AC133+. Le evidenze ottenute suggeriscono l’attivazione costitutiva del Wnt 
signaling attraverso l’espressione delle β-catenine attive (il cui stato defosforilato 
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permette il loro l’accumulo nel citoplasma e la migrazione nel nucleo, 
promuovendo la trascrizione dei geni target) e del WNT10B, proteina associata al 
pathway rigenerativo nelle cellule staminali ematopoietiche. La consapevolezza 
che una linea cellulare primaria possa meglio mimare il contesto leucemico in-vivo 
ha portato all’allestimento di una coltura cellulare (A46) selezionata per la frazione 
AC133, ottenuta dal sangue midollare di un paziente affetto da LMA. La strategia 
per valutare in vivo gli effetti funzionali correlati ai segnali indotti dalle A46, è stata 
quella di utilizzare il modello di zebrafish come biosensore. Le cellule leucemiche 
AC133+, negli embrioni di zebrafish, sono in grado di sviluppare strutture ectopiche 
secondarie attivando i marcatori dell’organizzatore che agiscono a valle del WNT 
pathway. La stretta associazione tra insorgenza tumorale e danno tissutale cronico 
è più volte emersa in letteratura. Inoltre durante il processo rigenerativo indotto da 
un danno tissutale è stato evidenziato, nell’omeostasi midollare, un’aumentata 
attivazione del signaling del Wnt/β-catenine. In accordo con quanto riportato in 
letteratura, i nostri risultati forniscono risultati a sostegno di una de-regolazione nel 
signaling rigenerativo Wnt-dipendente in pazienti affetti da LMA. 
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1.2 ABSTRACT 
Ample evidence exists in mouse models that acute myeloid leukemia (AML) 
develops through stepwise acquisition of collaborating genetic and epigenetic 
changes in self-renewing leukemia-initiating cells (LICs) that exhibit a committed 
myeloid immunophenotype. Recently, critical questions emerged regarding the 
characterization of LICs in the CD34+CD38- fraction and the AC133 antigen (a 
glycosylation-dependent epitope of CD133) seems to be one of the markers more 
appropriate to enrich for the LICs-containing fraction. The requirement of the 
Wnt/β-catenin pathway in the pathogenesis of acute myeloid leukemia (AML) has 
recently emerged in mouse models. However, its relationship to genetic programs 
promoting retention of self-renewing leukemia stem cells (LSCs) remains elusive. 
Hence, the need to identify transcriptional programs involved in the maintenance of 
a self-renewing state in LSCs. Given the predominant role of transcription factors 
(TFs) function in myeloid leukemia and recent progresses in reprogramming 
research for a critical role of TFs in the establishment and maintenance of cellular 
phenotypes, here we generated a specially designed transcriptional regulators 
(TRs) dataset to interrogate expression microarray data obtained from AC133+ 
cells in AML patients and healthy donors. Our data suggest that the canonical 
Wnt/β-catenin signaling is activated in leukemic human long-term reconstituting 
AC133+ restricted cells. In a series of molecular and functional studies we found 
that leukemic cells AC133+ synthesize and secrete WNT10B, a hematopoietic 
stem cells (HSCs) regenerative-associated molecule, and increase the levels of 
dephosphorylated β-catenin. Nevertheless, AML AC133+ cells, in zebrafish 
embryos, are able to develop ectopic structures by activating organizer markers 
that act downstream of the Wnt pathway. In light of the long-known association 
between cancer and chronic tissue injury, and because of the higher homeostatic 
range of Wnt/β-catenin signaling occurring during regeneration upon an acute 
injury, altogether our data provide compelling evidence that regeneration-
associated Wnt signaling exceeds the homeostatic range in human AML and 
affects responsive cells whose renewal is promoted by Wnt pathway activity. 
 
	  	   IV	  
INDEX        
	  
1.1  SOMMARIO        I  
  
1.2  ABSTRACT                 III 
	  
2.  INTRODUCTION        1 
	  
2.1 Stem Cells and their hallmarks     1 
	  
2.2 Hematopoietic Stem Cell (HSC) and Hematopoiesis  3 
  
2.2.1 Hematopoietic Stem Cell     3 
	  
2.2.2 Hematopoietic Hierarchy     5 
	  
2.2.3 HSC and their niche      6 
	  
2.3 Leukemia Initiating Cell (LIC)       11 
	  
2.3.1 Definition and origin of LIC in Acute Myeloid  
               Leukemia (AML)      11 
	  
2.3.2 CD34+CD38- as population enriched for the LIC: 
               is that the only one?      14 
	  
2.3.3 AC133: the molecule of the moment    16 
	  
 2.4 Emerging transcriptional programs in AML pathogenesis 17 
	  
2.4.1 Transcriptional factors are pivotal for AML development 17 
	  	   V	  
	  
2.4.2 Hedgehog signaling in cancer    20 
	  
2.4.3 WNT signaling and its role in the stem cell self-renewal 24 
	  
3.  AIM OF THE STUDY AND STRATEGIES    28  
	  
4.  MATERIALS AND METHODS      30 
	  
4.1 Collection of patients’ samples and normal hematopoietic cells 30 
	  
4.2 Cell sorting and flow cytometry     30 
 
4.3 Microarray expression analysis and bioinformatics analysis 31 
	  
4.3.1 Sample preparation and Affymetrix platform.  31 
	  
4.3.2 A genome-wide approach: the functional  
               enrichment  analysis.      31 
	  
4.3.3 Generation of an evolutionarily conserved  
               human transcriptional regulators dataset.   32 
	  
4.3.4 Functional enrichment using the Bioconductor  
              GOstats package.      34 
	  
4.4 Immunoblot        35 
	  
4.5 Immunofluorescence and image analysis    36 
	  
4.6 Primary cell culture       37 
	  	   VI	  
	  
4.7 Wnt/β-catenin responsive luciferase assay    37 
	  
4.8 Zebrafish models and transplantation procedures   38 
	  
5.  RESULTS         39 
	  
5.1 AC133 positivity is a widespread feature of AML blasts  39 
	  
5.2 Identification of a common transcriptional  
     regulation signature in AC133 positive cells of AML patients 41 
  
5.3 Activation of Wnt signaling resulted in diffuse expression of 
     the hematopoietic regenerative molecule WNT10B   42 
	  
5.4 WNT10B expression in AC133+ leukemic primary cell culture 46 
	  
5.5 Transplantation in zebrafish embryo of AC133+ leukemic  
      primary cell culture induces ectopic axial structures formation 
      by Wnt signaling activation      48 
	  
6.  DISCUSSION        50 
	  
7.  CONCLUSIONS        53 
  
8.  REFERENCES        55 
	  
9.   SCIENTIFIC PRODUCTS      62 
	  
10. ACKNOWLEDGMENTS       63 
 
11. SUPPLEMENTARY TABLES      67  
	  
	  	   VII	  
 
	  
INDEX OF FIGURES  
 
Figure 1.  Cellular hierarchy of the hematopoietic system.      5 
Figure 2.  Endosteal bone surfaces are lined with stromal cells.      7 
Figure 3.  The two different locations of hematopoietic stem cells (HSCs)   
                 in the mouse bone marrow.       8 
Figure 4.  Comparison of self-renewal during hematopoietic stem cell  
                 development and leukemic transformation    12 
Figure 5.  Model of leukemia development from block myeloid differentiation 19 
Figure 6.  Hedgehog signaling pathway      21 
Figure 7.  Hedgehog pathway and tumorigenesis    22 
Figure 8.  Canonical Wnt/β−catenin pathway     25 
Figure 9.  Strategies applied in the PhD project     29 
Figure 10. Bioinformatic analysis of data derived from microarrays analysis. 33 
Figure 11. Gene Ontology Tree from the enrichment analysis   35 
Figure 12. Immunostained AC133 positive cells localized in chromatic  
                  islands in AML BM biopsy      39 
Figure 13. Flow Cytometric representation of AC133 expression in a healthy  
                  donor and AML#42.                   40 
Figure 14. Distribution of AC133+ expansion in AML samples and  
                  healthy donors       40 
Figure 15. Model of transcriptional regulators involved in AML pathogenesis 42 
Figure 16. Expression of active β-catenin (ABC) in AML samples  43 
	  	   VIII	  
Figure 17. Expression of WNT10B in AML BM smear and biopsy.  43 
Figure 18. WNT10B/β-Catenin double staining in AML patients   44 
Figure 19. WNT10B/β-Catenin pathway is activated in AML patients.  45 
Figure 20. WNT2B is activated in AML patients     45 
Figure 21. Dot plots of the immunophenotype analysis from AML#46 BM  
                  MNCs at diagnosis and after selection    46 
Figure 22. TOPFlash reporter assay showing luciferase expression driven 
                  by 8 TCF/LEF binding sites      47 
Figure 23. A46 AML cells induce ectopic gene zebrafish embryos  49 
Figure 24. A46 AML cells induce secondary body axes formation in  
                  zebrafish embryos       50 
          
      
 
 
 
 
 
 
 
 
 
 
 
 
	  	   IX	  
 
 
LIST OF ABBREVIATIONS 
 
 
LMA = Leucemia mieloide acuta 
HSC = Hematopoietic Stem Cell 
LIC = Leukemia Initiating Cell 
CSC = Cancer stem cell 
AML = Acute Myeloid Leukemia 
TR = Transcription regulators 
Wnt = wingless-type MMTV integration site family 
Shh = Sonic Hedgehog 
Hoxb4 = Homeobox B4 
Bmi-1 = BMI1 polycomb ring finger oncogene 
Lnk = Lymphocyte-specific adapter protein 
FGF-1 = Fibroblast growth factor-1 
CFU-S = Colony forming units-spleen 
BM = Bone marrow 
CMP = Common myeloid progenitor 
CLP = Common lymphoid progenitor 
LMPP = Lymphoid-primed multipotent progenitor 
LT-HSC = Long term hematopoietic stem cell 
ST- HSC = Short term hematopoietic stem cell 
MPP = Multipotent progeniors 
GMP = Granulocyte-monocyte progenitor 
MEP = Megakaryocyte-erytrocyte progenitor 
SNO = N-cadherin-expressing osteoblasts 
CXCL-12 = CXC-chemokine ligand 12 
CAR = CXCL-12-abundant reticular 
ECM = Extracellular matrix 
BMPRIA = Bone morphogenetic protein receptor type IA 
PTH = Parathyroid hormone 
BMCE = Bone-marrow sinusoidal endothelial cells 
VCAM1 = Vascular cell adhesion molecule 1 
LSC = Leukemia Stem Cell 
LS-ICs = SCID leukemia-initiating cells 
NOD/SCID = Nonobese diabetic/ several compromise immunodeficient. 
WT1 = Wilms tumor 1 
AML1-ETO = Acute myeloid leukemia 1 protein - Eight twenty one protein 
BCR-ABL = Breackpoint cluster region – Abelson oncogene 
PML-RARα = Promyelocytic leukemia – Retinoic Acid Receptor α 
MLL = myeloid/lymphoid or mixed-lineage leukemia 
MAb = Monoclonal antibody 
TIC = Tumor Initiating cell 
ALL = Acute lymphoblastic leukemia 
ITD = Internal tandem duplication 
CML = Chronic Myeloid Leukemia 
hnRNPE2 = heterogeneous nuclear ribonucleoprotein E2 
IL-3Rα = Interleukin-3 receptor alpha 
C/EBPα = CCAAT/enhancer binding protein 
RUNX1 = runt-related transcription factor 1 
CBFβ-MYH11= Core binding factor beta - myosin, heavy chain 11 
	  	   X	  
FAB = French-American-British classification 
SPI1 = SFFV proviral integration 
iPS = Induced pluripotent stem 
Oct4 = Octamer-binding protein 4 
Sox2 = SRY-related HMG-box 
Klf4 = Kruppel-like factor 4 
c-Myc = myelocytomatosis viral oncogene homolog 
Hip = huntingtin interacting protein 1 
Ptch = Patched 
Smo = Smoothened 
Sufu = Suppressor of fused 
Gli = glioma-associated oncogene family zinc finger 
BCC = basal-cell carcinoma 
HH = Hedgheog 
SHH = Sonic/Hedgheog 
BMP4 = bone morphogenetic protein 4 
TGF-β = transforming growth factor beta 
AF9 = ALL1-fused gene from chromosome 9 protein 
APC = adenomatous polyposis coli 
Tcf/LEF = Transciption factor / lymphoid enhancer-binding factor 1 
Fz = Frizzled 
LRP5/6 = low density lipoprotein receptor-related protein 
GSK3β = glycogen synthase kinase 3 
Notch1 = Neurogenic locus notch homolog protein 1 
PPARδ = peroxisome proliferator-activated receptor delta 
PI3K/AKT = phosphoinositide-3-kinase / v-akt murine thymoma viral oncogene homolog  
FLT3 = fms-related tyrosine kinase 3 
SMYD3 = SET and MYND domain containing 3 
DKK = dickkopf homolog 
PROP-1 = prophet of Pit1, paired-like homeodomain transcription factor 
PYGO2 = Pygopus 2 
KLHL12 = kelch-like 12 
E2F1 = E2F transcription factor 1 
DACT 1= dapper, antagonist of beta-catenin, homolog 1 
HBP1 = HMG-box transcription factor 1 
STAT3 = signal transducer and activator of transcription 3 
ABCC = ATP-binding cassette, sub-family C 
DLX3 = distal-less homeobox 3 
MARK4 = MAP/microtubule affinity-regulating kinase 4  
TNTG = Tris-NaCl-Triton-Glycerol 
BSA = Bovin Serum Albumin 
ABC = Active β catenin 
CM = Conditioned Medium 
WISH = wholemount in-situ hybridization 
DAPI = 4',6-diamidino-2-phenylindole 
IQR = Interquantile range 
MNC = Mononuclear cells 
hpf = hour post fertilization 
boz = bozozok 
sqt = squint 
gsc = goosecoid 
Cnh = chordoneural hinge 
n = notochord 
ntl = no tail 
pax2a = paired box 2 
OV = Otic vesicles 
OS = Optic Stalk 
e = eye 
MHB = midbrain-hindbrain boundary 
 
	   1	  
2. INTRODUCTION  
2.1 Stem cells and their hallmark 
Stem cells are defined by their ability to self-renew, which means they are 
replenished by leaving at least one identical copy of themselves behind after each 
cell division, and to differentiate to all the mature cells of the organ or tissue to 
which they belong1. Both characteristics need to be full-filled. Self-renewal without 
differentiation is what bacteria and other unicellular organisms do, and 
differentiation without self-renewal is the hallmark of cells in developmental transit 
between stem cells and mature cells. Thus, the ultimate test for a candidate stem 
cell is that it, as a single cell, should be able to completely recreate the tissue from 
which it is derived. This criterion, in its strictest sense, is to date only fulfilled by 
murine hematopoietic stem cells (HSCs)2, and might not be applicable to all kinds 
of stem cells. 
Stem cells are classified by the diversity of their progeny into: 
 TOTIPOTENT STEM CELLS are one of the most important stem cell types 
because they have the potential to develop to any cell found in the human 
body. Moreover they have the ability to replicate in unlimited numbers 
without lose their total potency thus they can create an entire organism.  
 
 PLURIPOTENT STEM CELLS are self-replicating cells that have the 
potential to develop into cells and tissues of the three primary germ layers 
(ectoderm, mesoderm, endoderm).    
 
 MULTIPOTENT STEM CELLS are unspecialized cells that have the ability 
to self-renew for long periods of time and differentiate into more 
specialized cells with specific function. Multipotent stem cells are 
essentially committed to produce specific cell types that give rise to a 
specific tissue. 
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Recently a number of papers have been described an unexpected plasticity of 
adult tissue stem cells blood which could be turned into heart3-5, pancreas6-7, 
muscle8-10, brain11-12, liver13-14, skeletal15-16 or more tissues, and stem cells from 
other tissues could be turned into blood17,18,19. Several models have proposed 
different possible mechanisms responsible of this plasticity, such as 
transdifferentiation of tissue specific stem cells into other tissue lineages; de-
differentiation to a more primitive and multipotent stage with subsequent re-
differentiation along a different lineage; the simultaneous occurrence of many 
different tissue restricted stem cells residing in the same organ; the existence of 
rare pluripotent stem cells with the capacity to generate progeny of all germ layers; 
or fusion of a stem cell (or any cell) with a cell of a different lineage. A stem cell can 
self renew by two different types of cell divisions either by a symmetrical division, 
where both daughter cells are stem cells, and which therefore expands the stem 
cell pool, or by an asymmetrical division, where one daughter is a stem cell and 
the other enters differentiation, leading to a steady state with regard to the stem 
cell compartment. In a third, non self-renewing type of division is the stem cell 
symmetrically producing two differentiated daughters, which depletes the stem cell 
pool. Much has been made of the idea that asymmetric division is a characteristic 
trait of stem cells. However, it seems obvious that most, if not all, stem cells at 
times divides mainly (or perhaps even exclusively) symmetrically to expand 
themselves, as for example during embryonic development, or during wound 
healing or regeneration; and therefore this trait cannot be necessary for the stem 
cell identity20. Very little data exist on the mode of division of mammalian stem cells 
in vivo20, 21, and it is theoretically conceivable (even if unlikely) that stem cells 
upholds their activity mainly, or even exclusively, by symmetrical divisions, 
producing either more stem cells or more differentiated progeny, depending on the 
needs of the organism. The scarcity and quiescence of most stem cells in vivo 
makes this question technically very challenging to approach. Regardless of the 
mode of cell divisions, stem cells can perpetuate themselves and serve their host 
during a life time and beyond, and recent years have seen a dramatic progress in 
identifying signalling pathways influencing HSC self renewal, such as Wnt22,23, 
Notch, sonic hedgehog (Shh)24, Hoxb4 25-28 , Bmi-1, Lnk , and thrombopoietin 29. 
The use of extrinsic signalling to amplify HSCs, like cytokines and growth factors, 
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has shown at best very limited expansion30-35, with perhaps recent reports of 
purified Wnt3a protein, fibroblast growth factor-1 (FGF-1) 36 and angiopoietin-like 
proteins37 expanding murine HSCs as notable exceptions. The quest for promoting 
HSC self renewal continues, however, since success could clinically benefit HSC 
transplantations where donor cells are limited in numbers (such as adult patients 
receiving cord blood transplants) or where large doses of HSCs are desired to 
overcome immunological barriers (such as for haploidentical transplantations). 
Mastering HSC self-renewal can also enhance gene delivery to HSCs for gene 
therapy38. The most striking feature of stem cells is that they can self renew: i.e. 
produce exact copies of themselves. It is often stated that stem cells can perform 
three kinds of cell divisions: symmetrical divisions producing two new stem cells, or 
asymmetrical divisions producing one stem cell and one daughter cell which 
commits to differentiation, or symmetrical divisions in which two committed 
daughter cells are produced. It is unclear what influences the HSC to choose either 
self-renewal or differentiation, but most believe that the decision is largely 
stochastic, or random – which would imply that a true HSC inherently, at the same 
time, contain both choices, as yet unrealized. However, once the differentiation 
choice is realized in cell division, the HSC status of the preceding cell collapses 
and considering that we do not know to what extent a cell can differentiate without 
dividing suggests further complexity.  
	  
2.2 HEMATOPOIETIC STEM CELLS AND HEMATOPOIESIS 
2.2.1 Hematopoietic stem cells 
HSCs are the best characterised of all adult stem cells for several reasons. First, 
they represent a minor subpopulation of dissociated cells within a floating organ, 
which is easily accessible in relatively large quantities. Second, they are vitally 
important providers of cells in an organ with a very high cell turn-over which may 
make both in vitro and in vivo assays faster and more yielding. A third reason is 
that the discovery of HSCs now dates almost half a century back, during which 
time instrumental methodological developments and insights have been made, 
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which have aided in the enormous progress in the field that we witness today. The 
first steps towards identifying HSCs was taken 1961 by Till and McCulloch, as they 
identified the colony forming unit – spleen (CFU-S)39. In their work on radiation 
sensitivity of tissues they stumbled upon the observation that bone marrow (BM) 
cells intravenously injected into lethally irradiated mice gave rise to macroscopically 
visible colonies of proliferating cells in the spleens of these animals. The colonies 
contained hematopoietic cells of all myeloid lineages at variable maturational 
stages, and were derived of recipient BM cells only, as irradiated but not 
transplanted mice never displayed such colonies. These colonies were termed 
colony forming units (CFUs). In order to prove that these colonies were derived 
from single cells, recipient mice received a sublethal irradiation dose, followed by 
injection of donor BM cells and subsequent further irradiation of the recipient up to 
a lethal dose, which exposed the donor BM cells in vivo to a significant irradiation 
dose, enough to confer recognizable chromosomal abnormalities in a proportion of 
the cells without killing them, and at the same time ablating the host HSCs. In 
some of the resulting colonies abnormal karyotypes were found by cytogenetic 
analysis in all investigated cells, and as chromosome breakage by irradiation is a 
random process, the clonality of the colonies were proven. In a third landmark 
paper they defined a stem cell as a cell that should have the capacity to give rise to 
differentiated progeny and have an extensive proliferative potential, two features 
they already had been able to assay in the spleen colonies, but a stem cell should 
also posses the capacity for self-renewal, such that an organ like the BM 
throughout the life-time of an organism always has stem cells that can continuously 
give rise to both differentiated progeny and retain a sufficient stem cell pool. In 
order to test the CFU-S for self-renewal capacity they injected dissected and 
resuspended CFU-S into secondary hosts, and found that primary spleen colonies 
often, or possibly always, contained cells capable of forming more spleen colonies. 
Thereby they proved that their CFU-S assay detected cells with the capacities for 
differentiation, extensive proliferation and self-renewal, and cautiously suggested 
that they might be HSCs. 
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2.2.2 Hematopoietic hierarchy  
Over the past four decades, much has been learned regarding the hematopoietic 
hierarchy that ultimately produces all mature blood-cell types from rare 
hematopoietic stem cells. This has been done to a greater detail in mice than in 
humans. The multipotent hematopoietic compartment is heterogeneous and 
consists of cells with decreasing levels of self-renewal capacity but increasing 
mitotic activity40.  
 
Figure 1. Cellular hierarchy of the hematopoietic system. HSCs can be 
subdivided into long-term self-renewing HSCs, short-term self-renewing HSCs and 
multipotent progenitors (red arrows indicate self-renewal).They give rise to 
common lymphoid progenitors (CLPs; the precursors of all lymphoid cells) and 
common myeloid progenitors (CMPs; the precursors of all myeloid cells). Both 
CMPs/GMPs (granulocyte macrophage precursors) and CLPs can give rise to all 
known mouse dendritic cells. (from Reya et al. Nature, 2001) 
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This compartment in mice can be phenotypically subdivided and prospectively 
purified into long-term HSCs (LT-HSCs, sustaining hematopoiesis for life), short 
term HSCs (ST-HSCs, sustaining hematopoiesis for up to 6 weeks) and 
multipotent progenitors (MPPs, without any self renewal capacity). A similar 
hierarchy is evident in humans, although it has not been phenotypically 
characterised41,42. For a long time, the first lineage branching point has been 
thought to be between myeloid and lymphoid cells. Common progenitors for these 
two cell populations (common myeloid progenitor, CMP, and common 
lymphoid progenitor, CLP) have been identified in both mice43,44 and humans45-
47. Recently, however, an alternative model has been proposed, where the first 
branching point is represented by a division between a common progenitor for red 
blood cells and megakaryocytes (the precursor for platelets) on the one hand and a 
progenitor with potential for all other lineages, called lymphoid-primed 
multipotent progenitor (LMPP), on the other48. An alternative way of interpreting 
the data has been offered though49. The CLP gives rise to committed precursors 
differentiating into the effectors cells of the lymphoid system; B-, T- and NK cells, 
and the CMP differentiates into granulocyte-monocyte progenitor (GMP), the 
common precursor for granulocytes and monocytes/macrophages, and the 
megakaryocyte-erytrocyte progenitor (MEP)43,47, although it is somewhat 
unclear if this last progenitor is a direct descendant from a MPP or from a CMP. 
None of these oligoclonal progenitors have any measurable self-renewal 
capacity40. 
	  
2.2.3 HSC and their nice 
Although during homeostasis, a small minority of HSCs are present in the 
circulation, the vast majority of HSCs are found in the bone marrow and they are 
thought to be localized in specific microenvironments called stem cell niches. A 
stem cell niche can be defined as a three-dimensional spatial structure in which 
one or several stem cells are housed. The function of a stem cell niche is 
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maintenance of stem cell numbers by allowing self-renewal in the absence of 
differentiation50. This type of niche may be thought of as a “self-renewing” or 
“homeostatic” niche51. Such a self-renewing stem cell niche would be the essential 
unit that maintains normal tissue homeostasis and would be located close to the 
border separating the niche from the non-niche microenvironment, which could 
provide signals that would induce differentiation and/or cell division. The regulation 
of the balance between HSC self-renewal and differentiation is dependent on the 
interaction between HSCs and the cells comprising the niches. Moreover, the 
maintenance of long-term dormant HSCs, which may serve as a reserve pool of 
stem cells to be activated in response to injury signals, is thought to occur in 
“dormant” niche51-52.  
 
Figure 2. Endosteal bone surfaces are lined with stromal cells. Spindle-shaped 
N-cadherin-expressing osteoblasts (SNOs) serve as niche cells to maintain 
quiescence and prevent differentiation of attached haematopoietic stem cells 
	   8	  
(HSCs). The quiescent endosteal niche would maintain dormant HSCs longterm. In 
response to injury, quiescent HSCs might be activated and recruited to the 
vascular niche. The self-renewing niche would contain quiescent HSCs 
intermingled with dividing HSCs. Self-renewing HSCs produce multipotential 
progenitors (MPPs) either by divisional or environmental asymmetry. More HSCs 
can be generated by symmetrical divisions which might provide the vascular niche 
with new HSCs. Whether HSCs long-term self-renew in the vascular niche remains 
to be determined, and it is probable that influx of HSCs from endosteal niches is 
necessary to ensure prolonged haematopoietic-cell production at the vascular 
niche. HSCs in the vascular niche promote differentiation and expansion along 
megakaryocytic and other myeloid-cell lineages, particularly in response to injury. 
MPPs can give rise to all haematopoietic lineages, including B-cell precursors 
attached to randomly distributed CXC-chemokine ligand 12 (CXCL12)-expressing 
stromal cells that constitute a B-cell niche. Unidentified T-cell precursors migrate to 
the thymus where they enter a microenvironment, promoting T-cell maturation. 
(from Wilson A. and Trumpp A. Nat Rev Immunol. 2006.) 
 
The localization and cellular composition of niches harbouring HSCs is still poorly 
understood. The main reason for this paucity of information is that unlike most 
other stem cells, HSCs are not spatially embedded in a solid tissue structure, but 
are migratory and hidden inside bones. Morphological and functional studies have 
indicated that HSCs and immature colony-forming progenitors reside in relation to 
the bone surface, away from the central cavity53-55. In the mouse BM two types of 
niches have been identified. 
 
Figure 3. The two different locations of hematopoietic stem cells (HSCs) in 
the mouse bone marrow. Dormant HSCs are in direct contact with specialized 
osteoblasts lining the endosteal surface of the bone. These cells are also in contact 
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with CXCL12-abundant reticular (CAR) cells that are found at the endosteum, but 
are more frequently associated with sinusoids. In the “endosteal niche” or 
“dormant niche,” CAR cells and osteoblasts together with stromal fibroblasts and 
potentially other cell types such as osteoclasts (not shown) generate a hypoxic 
environment with a dense extracellular matrix (ECM) that retains the dormancy of 
HSCs. Dormant HSCs are activated stochastically or in response to injury signals. 
Activated HSCs are located adjacent to perivascular CAR cells near sinusoids 
forming the vascular niche. On a self-renewing division, asymmetry is generated, 
which leads to the generation of two daughter cells: a multipotent progenitor (MPP) 
and an activated HSC. MPPs and/or their progeny enter the circulation through the 
fenestrated endothelium of sinusoidal microvasculature. (from Wilson A. et all.Ann 
N Y Acad Sci. 2007). 
	  
First the endosteal niche located at the endosteum of trabecular bone and 
comprising specialized osteoblasts, CXCL12-abundant reticular (CAR) cells 
osteoclasts and stromal fibroblasts. It has been observed that the bone tissue, and 
particularly the bone-forming osteoblast, by itself can support HSCs in 
cocultures56-58. More recently, several mutant mice in which hematopoiesis is 
defective as a consequence of primary defects in bone development or 
remodelling, have implicated osteoblasts and/or osteoclasts in the formation and 
function of the bone marrow HSC environment or niche59-61. In two different works, 
genetically engineered mouse models where used to convincingly show the 
osteoblast dependency of HSCs62,63. In the first, Zhang et al observed that in mice, 
in which the bone morphogenetic protein receptor type IA (BMPRIA) were 
conditionally inactivated, an increase in HSCs correlated with an increase in 
trabecular bone lining within the BM. Histological analysis revealed that long-term 
HSCs attached only to immature, spindle-shaped osteoblasts expressing N-
cadherin, and that N-cadherin adhered specifically to β-catenin on HSCs. The 
number of the spindle shaped osteoblasts correlated to a high degree with the 
increased number of HSCs, suggesting that the rise in HSC numbers where due to 
an expanded niche. In the second paper, Calvi et al. utilized the fact that 
osteoblasts are activated by parathyroid hormone (PTH), and constitutively 
expressed the PTH receptor under the control of a osteoblast-specific promoter 
(α1-collagen promoter) in mice. They observed, similar to Zhang et al., a 
correlation between increased osteoblasts and an increase in HSC numbers and 
function. In both papers, the increase in hematopoietic cells was restricted to 
HSCs. A third group reported the complementary finding, that induced osteoblastic 
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deficiency was followed by reduction of HSC numbers, and that restoration of 
osteoblast function normalized hematopoiesis64. The presence of a second 
specialized niche, the vascular niche has been recently postulated where HSCs 
are found next to CAR cells adjacent to BM sinusoids, which are low pressure 
vessels with a fenestrated. A close interaction between HSCs and endothelial cells 
is not unexpected because both lineages arise from a common embryonic 
precursor, the haemangioblast65. Bone-marrow sinusoidal endothelial cells 
(BMECs) are functionally and phenotypically distinct from microvasculature 
endothelial cells of other organs 66. Indeed BMECs constitutively express 
cytokines such as CXC-chemokine ligand 12 (CXCL12) and adhesion molecules 
such as endothelial-cell (E)-selectin and vascular cell adhesion molecule 1 
(VCAM1) that are important for HSC mobilization, homing and engraftment67-69. A 
vascular bone-marrow HSC niche has previously been predicted to form during 
HSC mobilization after myeloablation. Quiescent HSCs detach from the endosteal 
niche and migrate towards the centre of the bone marrow to the vascular zone from 
where they re-establish haematopoiesis66,68,70. The finding that CD150+ HSCs are 
attached to the sinusoidal endothelium now raises the possibility that a vascular 
bone marrow HSC niche might also exist during homeostasis71. It is probable that 
the pool of HSCs located in the vascular and self-renewing endosteal niches are 
freely exchanged to maintain homeostasis in a constantly changing haematopoietic 
environment. In addition, HSCs that are located in the self-renewing endosteal 
niche produce multipotential progenitors (MPPs) by divisional and/or environmental 
asymmetry. These cells give rise to myeloid-cell lineages as well as lymphocyte 
precursors. B-cell progenitors are uniformly distributed throughout the bone marrow 
attached to CXCL12-expressing fibroblasts (in the B-cell niche)72,73. Because 
deletion of osteoblasts results in extramedullary hematopoiesis74, the vascular 
bone marrow HSC niche alone might not be sufficient to maintain long-term 
hematopoiesis. This indicates that in the bone marrow the vascular niche might be 
a secondary niche, requiring an influx of HSCs from the primary endosteal niches. 
Collectively, the vascular and endosteal niches strongly cooperate to control HSC 
quiescence and self-renewing activity (and therefore HSC number), as well as the 
production of early progenitors to maintain homeostasis or re-establish it after 
injury. 
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2.3    LEUKEMIA INITIATING CELL (LIC) 
2.3.1 Definition and origin of leukemia initiating cell in acute myeloid 
leukemia 
The idea that only a minor subpopulation of so called “cancer stem cells” is 
responsible for maintenance of the neoplasm emerged about 50 years ago, with 
the best evidence with the discovery that the large majority of AML blasts do not 
proliferate and only a minority of them (≈ 1%) is capable of forming colonies when 
plated in a semisolid medium: the colonies generated under these conditions were 
called AML-CFU (colony-forming units)75. However, there are many doubts that 
AML-CFUs may represent leukemia stem cells (LSCs). The first demonstration of 
the existence of LSCs comes from the identification of a very rare population of 
human termed SCID leukemia-initiating cells (SL-ICs) that were capable of 
propagating acute myeloid leukemia in a xenograft transplant using NOD/SCID 
immunodeficient mice. The leukemias that developed in the secondary recipients 
closely resembled the human cancer, demonstrating that SL-ICs have long-term 
self-renewal capabilities and also determine the stage of the differentiation block 
during leukaemogenesis75. A given leukemia can be viewed as a newly formed 
aberrant hematopoietic tissue initiated by tumorigenic leukemic cells that have kept 
or reacquired the capacity for indefinitive proliferation through accumulated 
mutations. This concept suggests that leukemias are produced by a few leukemia 
initiating cells (LICs) that undergo an aberrant and poorly regulated process of 
organogenesis analogous to that of normal HSCs. Because normal stem cells and 
LICs share the ability to self-renew, as well as various developmental pathways, it 
has been postulated that newly arising cancer cells appropriate the machinery for 
self-renewing cell division that is normally expressed in stem cells and become 
leukemic as the result of accumulated mutations. Because normal stem cells and 
LICs share the ability to self-renew, it is possible that LICs are HSCs which have 
accumulated mutations and have become leukemic. There are two reasons to think 
that this may be the case. First, because stem cells have the machinery for self-
renewal already activated, maintaining this activation may be simpler than turning it 
on de novo in a more differentiated cell; that is, fewer mutations may be required to 
maintain self-renewal than to activate it ectopically. Second, by self-renewing, stem 
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cells often persist for long periods of time, instead of dying after short periods of 
time like many mature cells in highly proliferative tissues. This means that there is 
a much greater opportunity for mutations to accumulate in individual stem cells 
than in most mature cell types. 
	  
 
 
Figure 4. Comparison of self-renewal during haematopoietic stem cell 
development and leukaemic transformation. Unlike physiologic hematopoiesis, 
during leukemic transformation self-renewal pathways resulted impared, thus the 
leukemic stem cell become an easy target for mutations. If the mutational event 
arises from the progenitors compartment, it is necessary that the cells hit mantain a 
great self-renewal potential. (from Reya T. et all. Nature, 2001) 
 
 
Even restricted progenitor cells are less likely than stem cells to undergo neoplastic 
transformation because they proliferate for a much shorter period of time before 
terminally differentiating. Restricted hematopoietic progenitors of the lymphoid40 
and myeloid lineages all fail to self-renew detectably on transplantation. Thus, 
restricted progenitors would first need to acquire the extensive self-renewal 
potential of stem cells to have the opportunity to experience additional mutations 
that would lead to transformation. Nonetheless, restricted progenitors could 
potentially be transformed either by acquiring mutations that cause them to self-
renew like stem cells, or by inheriting existing mutations from stem cells such that 
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only a single mutation is required in the progenitors to cause transformation. Reya 
et al.40 and Passeguè et al.76 showed the necessity to highlight the cell that gives 
rise to the malignant transformation. Bonnet et al.77 have demonstrated that the 
cells capable of initiating human acute myeloid leukaemia (AML) in NOD/SCID 
(non-obese diabetic/severe combined immunodeficiency) mice have a 
CD34+CD38– phenotype in most AML subtypes, and thus have a phenotype 
similar to normal HSCs. Conversely, CD34-CD38+ leukemia cells cannot transfer 
disease to mice in the vast majority of cases, despite the fact that they exhibit a 
leukaemic blast phenotype. This suggests that normal HSCs rather than committed 
progenitors are the target for leukemic transformation78. Several studies have 
analyzed in depth the characteristic AML mutational events that can lead to the 
leukemogenic process, such as one of the most frequent chromosomal 
abnormalities in AML involve the 8;21 translocation, which results in AML1–ETO 
chimaeric transcripts in leukaemic cells. In human HSCs from patients in remission, 
AML1–ETO transcripts were found in a fraction of normal HSCs in the marrow79. 
These prospectively isolated HSCs and their progeny were not leukemic, and could 
differentiate to normal myeloerythroid cells in vitro. This indicates that the 
translocation occurred originally in normal HSCs and those additional mutations in 
a subset of these HSCs or their progeny were necessary for the leukaemia 
development. Miyamoto et al.79 suggested that the normal HSCs were 
CD34+CD38–Thy-1+, whereas the leukemic blasts were CD34+CD38–Thy-1–. 
Committed progenitors or even differentiated cells may also be the targets of 
malignant transformation. Leukemic fusion proteins such as BCR-ABL, PML-RARα 
can be transforming in myeloid progenitors and be able to induce leukemia. In de 
novo human leukemia, stem cells likely accumulate mutations necessary for the 
neoplastic proliferation even if the effects are detectable only in restricted 
progenitors. Thus, mutations accumulate in stem cells may lead to neoplastic 
proliferation of primitive progenitors. A final hypothesis of the malignant clones 
origin is the cell fusion between a HSC and a progenitor cell, in which one is 
normal and the other is partially transformed. In this case the cell fusion contributes 
to the full malignant potential. There are, however, any data supporting this 
sequence of events80-81.  
	   14	  
2.3.2 CD34+CD38- as population enriched for the LICs: is that the only one? 
LICs can be prospectively isolated based on surface-marker expression in the BM 
and peripheral blood of AML patients. Dick and Bonnet demonstrated that the 
leukemia initiating cells are identified by the immunophenotypic marker Lin- CD34+ 
CD38-. Their experiments showed that the capacity to transfer human AML to 
recipient mice resided exclusively within the CD34+ CD38- fraction. This cell 
fraction represents from 0.1 to 1% of the AML cell population contained all SL-ICs, 
whereas only clonogenic leukemia progenitors were found in other fractions. Upon 
transplantation of CD34+ CD38- cells, the entire cellular diversity was 
recapitulated, conclusively establishing that leukemia is a hierarchy sustained by 
rare LSCs, closely resembling normal development75. The mechanism that controls 
the hierarchical structure of the LICs poll derives from a heterogeneity in the self-
renewal potential of individual LICs. However recently Taussig et al.82 have shown 
that using anti-CD38 antibodies there was a profound inhibitory effect on the 
engraftment of both normal and leukemic repopulating cells. Thus by treating mice 
with immunosuppressive antibodies they have demonstrated that the SL-ICs from 
some AML samples were CD34+ CD38+, indicating a greater heterogeneity in the 
leukemic stem cell compartment. Moreover they observed from 7 AML patients that 
the SL-ICs was found also in the CD34+ CD38- and it is possible that these cells 
might have self-renewal potential. This appear to conflict with previous studies83, 77 
suggesting that SL-ICs are restricted to the CD34+ CD38-. The likely explanation 
for this apparent discrepancy lies in the heterogeneity of AML. The similarity of 
AML SL-ICs and normal repopulating cells (ie, CD34+CD38-) led some authors to 
hypothesize that AML is derived from an HSC. Others argue that the features of 
myeloid differentiation that define AML point to a progenitor origin. In support of 
this, it has been demonstrated that mouse myeloid progenitors can be transformed 
by the MLL oncogene84. It suggests that SL-ICs derived from a normal progenitor 
would have phenotypic features of progenitors with expression of CD34 and CD38. 
Notably, it has been demonstrated that one AML patient, which contained the 
translocation t(11;19)(q23;p13.1) involving the MLL oncogene showed SL-ICs 
detectable only within the CD34+CD38+ fraction82. Recent data, though, suggest a 
slightly different point of view: Barabe et al.85 used the MLL oncogene to transform 
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human cord blood cells into acute leukemia. This work highlighted that leukemic 
progenitors acquire self-renewal capacity and become a second generation of SL-
ICs (the first generation comprising SL-ICs derived from HSCs). In patients, similar 
events may occur; this is a possible explanation for the presence of 2 types of SL-
ICs in some samples: one with a primitive (CD34+CD38-) phenotype and one with 
a progenitor (CD34+CD38+) phenotype. Barabe et al reported that the second-
generation SL-ICs came to predominate as the leukemia evolved. The same thing 
may happen in some patients. By the time of diagnosis, second-generation SL-ICs 
with a progenitor phenotype (CD34+CD38+) may predominate and SL-ICs with a 
primitive phenotype (CD34+CD38-) may no longer be detectable. This explanation 
is an alternative to the direct transformation of normal myeloid progenitors. In 
conclusion, the hierarchical level at which the LICs are recruited in AML is still 
mostly elusive. The critical questions emerged regarding the characterization of 
LICs in the CD34+CD38- fraction suggests that other markers could be more 
appropriate to enrich for the LICs-containing fraction. For example CD44 was 
shown to be important for homing and engraftment of BCR-ABL positive CML and 
AML stem cells87. In a NOD/SCID transplantation model, antibody blockade by an 
anti-CD44 mAb led to a failed engraftment of leukemic cells, although the capacity 
to initiate leukemia when directly injected into bone marrow was maintained. The 
interleukin-3 receptor alpha (IL-3Rα) chain (CD123) was widely reported to be 
overexpressed on AML cells and on leukemic stem cells, but not on normal 
hematopoietic stem cells86. A neutralizing monoclonal antibody against CD123 
inhibited the IL-3- mediated survival of leukemic stem cells in vitro as well as 
homing, engraftment, expansion, and serial transplantation of AML cells in 
immunodeficient mice, with lower effects on normal hematopoietic cells87. Recent 
studies have shown that CD47 is upregulated on AML leukemic stem cells in 
comparison to normal hematopoietic stem cells and its level of expression on AML 
blasts is associated with poor prognosis. CD96 was described as a tumor marker 
for T-ALL and AML, characteristic for the AML stem cell in particular. Particularly, it 
was shown that the majority of CD34+CD38− AML cells in the majority of cases 
(19/29) abundantly express CD96, while the expression of this antigen is limited 
only to a minority of CD34+CD38− cells88. CD34+CD38−CD96+ cells are able to 
engraft immunodeficient animals88. CD96 is particularly expressed on AMLs with 
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mutations of the Wilms tumor 1 (WT1) gene and is associated with a poor 
prognosis. 
	  
2.3.3 AC133: The molecule of the moment 
Between the other markers that could be more appropriately used to enrich for the 
LICs-containing fraction, a specific mention must be given to the epitope CD133 
(prominin-1). It was the first identified member of the prominin family of pentaspan 
membrane proteins. The specific functions and ligands of the prominins are still 
relatively unclear, but they are distinct in their restricted expression within plasma 
membrane protrusions, such as epithelial microvilli and epididymal ductal epithelial 
sterocilia. In 1997, Yin et al.89 produced a novel monoclonal antibody (MAb) that 
recognized the AC133 antigen, a glycosylation-dependent epitope of CD133, 
whose restricted expression in CD34+ progenitor populations from adult blood and 
bone marrow and fetal liver cells implied its function as a marker of haematopoietic 
progenitor cells. AC133+ cells were capable of long-term repopulation in 
xenografted animals and were believed to be more primitive than CD34+ cells, as 
AC133 was absent from endothelial cells or fibroblasts. Due to its expression by 
hematopoietic progenitors, interest has been directed towards the potential of 
CD133 as a cell surface marker of adult stem cells. In hematopoietic lineages in 
man, consistent with AC133 expression, CD133 antigen expression is restricted to 
CD34+ cells, although CD133 transcripts have been found in many human cell 
lines and differentiated cells90. Furthermore, AC133+/CD34+ cells have a higher 
clonogenic capacity and engraftment rate than AC133−/CD34+ cells91-92. 
Therefore, as AC133 is expressed only on stem and progenitor cells, whereas 
CD133 is also expressed on differentiated cells, the AC133 epitope is the most 
promising stem cell marker. Gallacher et al.93 showed that AC133+ cells were the 
only subset amongst a CD34−CD38−lineage− population from human cord blood 
that could form CD34+ cells in culture, with an engraftment capability in the bone 
marrow of NOD/SCID mice 400-fold greater than the AC133− subset. Lang et al. 
showed the benefit of CD133+ cells for human allogeneic transplantation; injection 
of either CD133+ or CD34+ cells from both matched unrelated and mismatched-
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related donors into ten patients produced successful reconstitution, but with a 
reduced T-cell depletion by the CD133+ selection94. Expanding evidence highlights 
the role of CD133 as a marker of tumor initiating cells (TICs) in various human 
tumours. CD133 was expressed in combination with CD44+ and α2β1hi in 
approximately 0.1% of cells within a large series of prostate tumours, irrespective 
of their grade or metastatic state. AC133+ cells undergo multi-lineage 
differentiation to neurons, astrocytes, and oligodendrocytes in vitro, and can 
recapitulate the original tumour phenotype in vivo, unlike their CD133− 
counterparts. An interesting study has been performed on childhood acute 
lymphoblastic leukemia (ALL). ALL cells capable of long-term proliferation in vitro 
and in vivo were derived from the CD133+/CD19- subfraction. Moreover, these 
CD133+/CD19- cells could self-renew to engraft serial nonobese diabetic–severe 
combined immunodeficient recipients and differentiate in vivo to produce leukemias 
with similar immunophenotypes and karyotypes to the diagnostic samples. Similar 
results were obtained using cells sorted for CD133 and CD38, with only the 
CD133+/CD38- subfraction demonstrating xenograft repopulating capacity. These 
findings suggest that leukemia-initiating cells in childhood B-ALL have a primitive 
CD133+/CD19- and CD38- phenotype. Therefore, growing evidence supports the 
importance of CD133/prominin-1 as a central defining factor in the TICs phenotype, 
highlighting it as a target for successful cancer therapy. 
	  
2.4   EMERGING TRANSCRIPTIONAL PROGRAMS IN AML PATHOGENESIS 
 
2.4.1 Transcriptional factors are pivotal for AML development 
Studies of human acute myeloid leukaemia led to the concept that cancer-
associated differentiation arrest is caused by mutated or dysregulated transcription 
factors.  
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Table 1. Examples of transcription factor mutations in patients with AML. 
(From Rosembauer F. et Tennen D., Nat Rev Immun, 2007) 
 
The involvement of aberrant transcription factor activity in human AML was first 
observed from common somatically acquired chromosomal translocations that 
result in oncogenic fusion products such as RUNX1–ETO (t(8;21)), CBFβ–MYH11 
(core-binding factor-β–myosin heavy chain 11; inv16), fusion proteins involving 
MLL (mixed lineage leukaemia; t11q23), and PML–RARα  (promyelocytic 
leukaemia–retinoic acid receptor-α; t(15;17)). More recently, small recurring 
mutations in defined regions of transcription factor gene coding sequences have 
been identified in patients with AML. In the granulocytic FAB system M2 subtype of 
AML, C/EBPα is the most frequently mutated transcription factor. This blocks 
granulocyte differentiation by reducing C/EBPα  function through a dominant-
negative effect of the transcriptionally inactive 30kDa isoform on the active 42kDa 
protein. Similarly, FLT3 with internal tandem duplication (ITD) mutations has been 
reported to decrease C/EBPα  expression and to increase C/EBPα  protein 
inactivation following phosphorylation of serine 21 of C/EBPα. The myeloid 
differentiation arrest in patients with chronic myeloid leukemia (CML) with blast 
crisis is also associated with reduced C/EBPα  activity, through a mechanism that 
involves induced inhibition of CEBPA mRNA translation by the heterogeneous 
nuclear ribonucleoprotein E2 (hnRNPE2)95. Collectively, C/EBPα disruption seems 
to be a central event in human malignancies of the granulocytic lineage, an idea 
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that is supported by mouse models. C/EBPα-deficient mice showed blocked 
granulocyte development, and accumulation of myeloid precursors similar to 
patients with AML96-97.Other myeloid transcription factors are also affected in 
myeloid cancer. RUNX1 is mutated in 9% of cases of AML, most frequently in the 
immature FAB system M0 subtype, and Runx1–/– mice develop a 
myeloproliferative syndrome98. Although no mutations have been reported in the 
IRF8 gene so far, its frequently shown the downregulation in patients with both 
AML and CML. In the case of PU.1, mutations in the SPI1 gene were identified in 
7% of patients with AML in one study, mainly in patients with the FAB system 
monocytic M4 and M5 subtypes. These mutations resulted in the decreased ability 
of PU.1 to synergize with interacting proteins, such as RUNX1 or JUN, in the 
activation of target genes. In contrast to the clear link between transcription factors 
coordinating early myeloid differentiation steps and leukaemia, it is less clear how 
relevant late-acting factors, such as C/EBPα, are for the transformation process. A 
plausible hypothesis is that they might act too late for their loss of function to 
contribute to the accumulation of proliferating progenitors99. How might altered 
transcription factors function lead to myeloid leukaemia? An attractive hypothesis is 
that progenitors at intermediate stages might be inherently pre-leukemic, this would 
explain why they are designed to proliferate rapidly for a short time to enlarge the 
progenitor pool, but after that, they immediately need to undergo differentiation. 
 
	   20	  
Figure 5. Model of leukemia development from block myeloid differentiation.  
The normally short-lived intermediate myeloid progenitors undergo rapid 
proliferation before they differentiate into functional immune cells. The balance 
between proliferation and differentiation is tightly controlled by stage-specific 
transcription factors. If dysregulated or mutated, these transcription factors fail to 
induce differentiation and therefore can cause a prolonged proliferation phase. This 
might place the progenitors at a higher risk of developing a true leukaemia owing to 
the random accumulation of additional cooperating events. CMP, common myeloid 
progenitor; GMP, granulocyte/monocyte progenitor; HSC, haematopoietic stem 
cell. (from Rosembauer F. et Tennen D., Nat Rev Immun, 2007) 
 
Failure to induce differentiation might result in a prolonged proliferation phase 
followed by the random accumulation of additional cooperating events because of 
an increased rate of cell division. This places the progenitors at much higher risk to 
ultimately develop true leukemia, a model that is similar to those put forward to 
explain the development of teratocarcinomas from embryonic stem cells. 
Transcription factors are the key gatekeepers in this process, and their 
dysregulation leads to a shift from the essential differentiation process to prolonged 
proliferation, thereby shifting the balance towards cancer. An important 
breakthrough that pose the importance of the transcription factors for the cell was 
achieved by Yamanaka and colleagues100 who succeeded in directly 
reprogramming fibroblasts into induced pluripotent stem (iPS) cells by transduction 
of the four transcription factors Oct4, Sox2, Klf4 and c-Myc . Another study showed 
that generating iPS cells from pro and pre-B cells by transduction with the 
reprogramming factors Oct4, Sox2, c-Myc and Klf4 and from mature B cells by the 
additional overexpression of C/EBPα or specific knockdown of the Pax5 
transcription factor indicate that specific combinations of reprogramming factors 
can reset the genome of terminally differentiated cells to a pluripotent state, 
suggesting that dysregulating the physiological expression of transcription factors 
can move on the cell through an oncogenic transformation. 
	  
2.4.2 Hedgheog signaling in cancer  
The Hedgehog signaling (HH) has been identified for the first time in Drosophila 
melanogaster, where it controls cell differentiation, the formation of organs, such as 
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the neural tube during embryogenesis and scientific studies, have revealed the 
three ligands involved, Sonic, Desert and Indian, are able to bind to 
transmembrane receptors Hip1, and Ptch1 Ptch2, expressed by the cells 
responsive to Hedgehog101. Shh (Sonic Hedgehog) is a glycoprotein, mainly 
studied in the development of the central nervous system during development as 
expressed by cerebellar Purkinje cells and is a major mitogen for cerebellar 
granule cell progenitors outside. Once secreted, binds Shh, Patched (PTCH), a 
receptor to twelve transmembrane domains, which inhibits another receptor with 
seven transmembrane passages, Smoothened (Smo), which is closely related to 
the family of Wnt receptors Frizzled pathway, has intrinsic catalytic activity and 
signaling. In the absence of the activity of Smo, the effectors of the Shh pathway, 
are kept in a cytoplasmic multiprotein complex that includes Fused proteins and 
Suppressor of Fused (Sufu). Seized in this way, Gli1 can not perform its function as 
a transcriptional activator, while two other members of the family, Gli2 and Gli3, are 
activated following a proteolytic cleavage assuming the role of transcriptional 
repressors. The binding of Shh to Patched activates Smo, then the complex 
containing Fused, and Sufu is disassembled, Gli1 is thus released while cutting 
Gli2 and Gli3 is locked. Among the target genes of Gli1 to note: the same Gli1, Wnt 
genes encoding factors, PTCH, n-myc, c-myc and cyclin D1101. 
 
 
Figure 6. Hedgehog signaling pathway. On the left side is represented the 
Hedgehod pathway inactive. Ptch receptor inhibits Smo activity and Gli factors 
remain bound to the cytoplasmatic complex formed by Fused and Sufu. On the 
right side, the activation of the pathway is mediated by either Sonic, Desert or 
Indian that bind Ptch receptor. This leads to Smo activation and the translocation of 
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Gli in the nucleus, where targets genes transcription can start. (from Pasca di 
Magliano M. et al, Nat Rev Cancer, 2003) 
The HH pathway is involved in the process of tumorigenesis, because scientific 
studies have shown that Shh mutations are present in squamous cell carcinoma 
basal-skin, and in some cases, in medulloblastoma and in breast cancer.  
Activating mutations in Smo have been identified in 10-20% of squamous cell 
cancers of the skin basal-cell carcinoma(BCC) and the amplification of the 
transcription factor Gli1 was originally identified in gliomas. In addition, inactivating 
mutations of Ptch1 and Sufu, have been identified in approximately 20% of human 
medulloblastomas that present preferentially but not exclusively, desmoplastic 
morphology. More precisely, Sufu mutations were associated with an increased 
risk of developing medulloblastoma in humans, while Ptch1 mutations were 
identified in patients with Gorlin syndrome, a disease characterized by a high 
incidence of BCC and medulloblastoma102.   
 
Figure 7. Hedgehog pathway and tumorigenesis. Mutations of HH pathway 
involved in different tumors. (from Pasca di Magliano M. et al, Nat Rev Cancer, 
2003) 
 
The deregulation of the SHH pathway has been mainly studied in solid tumors, and 
there is not much literature about its involvement in haematological malignancies 
103. It is interesting, however, the proposed study by Bhardwaj et al.104, which 
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highlights the role of SHH in the proliferation of pluripotent hematopoietic precursor 
cells, the researchers point out that HH and receptors PTCH and Smo and 
consequently the transcription factors downstream of the cascade, such as the, are 
expressed by precursor cells of the hematopoietic and stromal cells from the stem 
cell niche. Of particular interest is the lack of expression of transcription factors of 
the Gli family in the cells of the hematopoietic system have already committed to a 
lineage differentiation, suggesting the hypothesis that the SHH pathway is 
important for the maintenance of cell self-renewal stem, but not essential for the 
differentiation process. Bhardwaj et al also highlight the importance of the niche in 
maintaining stem cell self-renewal, because of the activity of the cytokine BMP4 
(Bone Morphogenetic Protein 4), a member of the family of TGF-β growth factors, 
released from the cells stromal cells, the SHH pathway is still active. Multiple 
studies have explored the role of the Hh pathway in development, but relatively few 
studies have addressed the role of Hh signaling in normal hematopoietic 
development and leukemogenesis To define its role it has been assessed the 
consequences of conditional deletion of the Smoothened (Smo) allele in an in vivo 
knockout mouse model105. Hoffman suggested that the Hedgehog pathway is not 
required for hematopoietic homeostasis in the adult mouse. Recently, data suggest 
that Hh signaling may play an important role in leukemia stem cell function in a 
BCR-ABL-induced model of murine hematopoietic disease106-107. Although Hoffman 
et al. observed no impact in MLL-AF9-mediated leukemogenesis in the absence of 
Smo, suggesting that the pathway does not play a critical role in initiation of 
leukemia, it remains plausible that Hh signaling could be effectively targeted in 
leukemias that arise de novo, or that there are allele-specific differences in 
requirement for Hedgehog signaling. Taken together, these findings demonstrate 
that Hh signaling is dispensable for normal hematopoietic development and 
hematopoietic stem cell function, indicating that targeting of Hh signaling in solid 
tumors is not likely to result in hematopoietic toxicity. Furthermore, the Hh pathway 
may not be a compelling target in certain hematopoietic malignancies. 
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2.4.3 WNT signaling and its role in the stem cell self-renewal 
In the absence of Wnt signal, APC fosters the degradation of the oncogene 
β−catenin and prevents its entry into the nucleus. Wnt stimulation, loss of APC 
protein function, or of its associated partner Axin, all lead to the stabilization of 
β−catenin and to its increased concentration in the nucleus. β−catenin can then act 
as a transcriptional co-activator by associating with the Tcf/LEF family of 
transcription factors. A complex of APC with Axin and other proteins targets β-
catenin for proteasomal degradation by scaffolding an association between β-
catenin and kinases whose activities lead to β-catenin ubiquitinylation. This action 
is abrogated by the recruitment of the degradation complex to the membrane upon 
Wnt activation of a receptor complex that includes Frizzled (Fz), a relative of Smo, 
and LRP5/6. Any lesion causing β-catenin accumulation through the disruption of a 
degradation complex component or by mimicking complex recruitment to the 
receptor would be expected to promote tumour formation. Many scientific studies 
have highlighted the important role of the Wnt pathway in mechanisms regulating 
hematopoietic stem cells and more specifically, Reya et al.22 have demonstrated 
via the inhibition of Frizzled receptor in vitro and in vivo, that the mitotic division of 
hematopoietic stem cells is determined by activation of Wnt signaling highlighting 
the role of WNT in the development of HSC. The regulation of self-renewal appears 
to be mediated by their own WNT proteins produced by stromal cells and the niche 
and in some cases from the same hematopoietic stem cells through paracrine and 
autocrine mechanism. 
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Figure 8. Canonical Wnt/β-catenin pathway. At the left, in absence of Wnt 
ligand, β-catenin are complexed with axin-APC-GSK3β and once phosphorilated, 
they are degradated. In the right, Wnt ligand binds its frizzled receptor, that induce 
the release of β-catenin from axin-APC-GSK3β complex and the migration of β-
catenin in the nucleus where it promotes the transcription of target genes. (from 
Reya et all. Nature, 2005) 
 
 
 Functional studies in vitro have shown that the Wnt proteins work in synergy with 
Steel factor (also known as Stem Cell Factor), to promote cell growth, inhibiting 
simultaneously murine hematopoietic progenitor differentiation. It was also shown 
that β-catenin Wnt3A protein are able to promote self-renewal of murine stem cells 
in vitro and to reconstitute the hematopoietic system in murine irradiated models in 
vivo. The same effects detected in mouse models are present at the level of the 
human hematopoietic system. For example, the treatment of hematopoietic 
progenitors with Wnt5A in presence of stromal cells, promotes the expansion of 
progenitors in vitro and treatments with the medium conditioned by Wnt5a result in 
an increase of repopulating stem cells in NOD-SCID mouse models 
xenotransplanted. All the studies conducted in vitro and in vivo, have supported the 
hypothesis that Wnt signaling have a central role in the self-renewal of 
hematopoietic stem cells and progenitors. Reya et al.109 have shown how each 
component of the Wnt signaling is necessary for self-renewal of the hematopoietic 
stem cell. The in vitro studies have revealed that the expression of activated β-
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catenin allows the maintenance of the immature state of stem cells, but at the 
same time also the proliferation of the cell pool which appears to be increased by 
20-48 times compared to the number of cells present at the start. Experiments in 
vivo demonstrated that the hematopoietic stem cell niche respond to the canonical 
Wnt signal through the activation of nuclear components such as Tcf/Lef 
determining the increase of self-renewal through the up-regulation of transcription 
factors that control the cell cycle, such as HoxB4 and Notch1. Reya et al. have also 
observed that the Wnt pathway dysregulation and possible mutations in 
components of the Wnt signaling pathway are present in blood diseases with 
special emphasis on myeloid leukemias, where it is involved in both the acute and 
the chronic form. Chronic myelogenous leukemia is characterized mainly by 
translocation t(9; 22) which determines the fusion product BCR-ABL; it has been 
also shown that the β-catenin play a crucial role in maintaining the pool of tumor 
cells which is probably necessary to generate the BCR-ABL mutation. The 
dyregulation of the Wnt pathway was also observed in acute myeloid leukemia, 
both in presence and absence of mutations that characterize the classical disease. 
Studies conducted by Mikesch et al. have revealed the association between AML1-
ETO fusion products, PML-RARα and PLZF-RARα and activation of Wnt signaling, 
which are able to determine the transactivation of the TCF / LEF complex by 
increasing β-catenin expression, which in turn leads to target genes transcription 
such as cyclin D1, c-myc and PPARδ. Thus, it emerged an association between 
the chromosomal translocations that characterize different forms of acute myeloid 
leukemia and the Wnt pathway, mediated by the globin appease, co-activator 
complex TCF / LEF. The leukemogenic process is also determined by activating 
mutations of FLT3 receptor tyrosine kinase III, present in 30% of patients with AML. 
Analysis conducted using microarray technology in cell lines 32D/Flt3-ITD, have 
revealed that Wnt receptor Frizzled-4, can be induced and activated by FLT3 in 
myeloid progenitors, resulting in Wnt signaling activation. It is also interesting to 
note that the increase in β-catenin level appears to be associated with 
transcriptional activation of the complex TCF / LEF, but also to the induction TCF-
dependent of c-myc. The observations reported by Simon et al. show that Gsk3β 
turns out to be inactivated by phosphorylation of Akt. The PI3K/AKT signaling 
cascade is in fact to be activated in several cases of AML and in particular is 
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activated by mutations of FLT3-ITD, suggesting that Wnt signaling in the growth of 
leukemic patients is partly due to inactivation of GSk3β. The results therefore 
suggest that the FLT3-ITD mutations may contribute to the leukemogenic process 
in association with the Wnt activation signaling109. Recent studies conducted by 
Jamieson et al., showed alterations of the Wnt pathway in leukemia cells, 
regardless of the presence of chromosomal alterations. Several cases of AML 
analyzed by Simon et al. show alterations of various components of the signaling 
cascade, such as Wnt1, Wnt2b and Lef1, as a potential mechanism of up-
regulation of signaling β-catenine/TCF. β-catenin appear to be expressed at 
different levels in patients with AML, as affected by post-translational regulation of 
Wnt-mediated pathway, their expression seems to be correlated with the ability to 
clone proliferation of AML colony-forming cells, and then with the cell self-renewal. 
Studies by Duncan et al., support the hypothesis that Wnt signaling plays a role of 
fundamental importance in the development of leukemia, even in the absence of 
specific mutations, but in close correlation with other deregulated pathways, such 
as that of Akt and Notch109. 
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3. AIM OF THE STUDY AND STRATEGIES  
The existence of a subpopulation of rare cancer stem cells (CSCs) responsible for 
maintenance of the neoplasm has been postulated and substantial evidence 
emerged in the literature in recent years110. The data suggesting that the leukemic 
stem cell (LSC) pool, like the normal hematopoietic stem cell (HSC) compartment, 
is organized as a hierarchy of distinct stem cell classes with decreasing self-
renewal capacity75,77, is the most compelling evidence to date of the stem cell 
origin of acute myelogenous leukemia (AML). Understanding the genetic and 
molecular regulations of the self-renewal programs and an appreciation of how 
perturbations in this regulation initiate proliferative diseases such as leukemia is a 
major challenge of the medical research. Annotation of the draft sequence of the 
human genome has opened up the possibility of applying novel genomic 
approaches to the characterization of molecular pathogenesis of human disorders. 
Among genomic screening methods, DNA-microarray analysis has to date 
provided the greatest insight into leukemogenesis.  
Considering the relevant role of transcription factors in myeloid leukemogenesis, in 
order to investigate the common transcriptional programs in the AC133+ stem cell 
fraction from AML patients, we generated an ad hoc transcriptional regulators 
(TRs) dataset to interrogate expression microarray data obtained from AC133+ 
cells in AML patients and healthy donors.  
 The main goal of the research activity performed by introducing biological 
(AC133+ cell fraction selection) and bioinformatic (TR-dataset restricted 
analysis) filters is the development of a transcriptional circuitry model in 
which defined master “executer” genes acting to induce a stronger 
(possibly leukemogenic) response of the final “player” genes on self-
renewal programs (Figure 9 top).  
 To validate the in silico results obtained from a functional enrichment 
analysis, AML and healthy donors BM biopsies, AC133+ fractions and BM 
smear were investigated using immunofluorescence and immunoblot 
strategies (Figure 9 bottom).  
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 In order to investigate the circuitry model emerged from transcriptional 
studies a hematopoietic primary stem cell culture was established. The 
primary cell culture was set up using the purified 
AC133+CD34+CD117+CD38- fraction obtained from a patient affected by 
AML M2 with 46XY karyotype and harbouring an Flt3 ITD mutation. 
Establishing of a powerful cellular model for LSC is an important goal of 
the project because it represents the best starting point to evaluate the 
deregulated pathways in AML.  
 In recent years the zebrafish has emerged as a valuable organism in which 
to model leukaemogenesis111. Using the zebrafish model as biosensor 
allowed us to investigate the molecules released in the microenvironment 
by the AC133+ leukemic cells and whether these molecules interfere with 
the physiological development of zebrafish main tissues. 
 
Figure 9. Strategies applied in the PhD project. AML= acute myelogenus 
leukemia patients; HD= healthy donors. BM= bone marrow 
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4. MATERIALS AND METHODS 
4.1 Collection of AML patients and healthy donors sample of hematopoietic 
cells. 
Bone marrow (BM) mononuclear cells were collected from 33 diagnosed AML 
patients and 10 healthy donors according to Niguarda Hospital’s Ethical Board 
approved protocols (116_04/2010). Human adult BM cells obtained from 
consenting healthy donors and patients were isolated according to standard 
procedures using Lymphoprep (Axis-Shield PoC AS) from the BM drawn from the 
posterior iliac crest. (Supplementary Table 1) 
4.2 Cell sorting and flow cytometry. 
The AC133+ cell fraction was isolated by immunomagnetic separation after 
labelling with CD133/1 (AC133)-biotin antibody and anti-biotin MicroBeads on LS 
columns and Midi MACS separator (Miltenyi Biotec). Unselected BM-MNC, 
CD133/1-positive (AC133+), and CD133/1-negative (AC133−) cells were incubated 
for 20 minutes at room temperature in the dark with the appropriate monoclonal 
antibody (mAb) mixture, at a concentration deriving from specific titration 
experiments. MAbs were directly conjugated with the fluorochromes fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP), 
and allophycocyanin (APC), and combined for four-color analysis. Each sample 
was incubated with the following mAbs panels: CD34-FITC/CD133/1-PE/CD45-
PerCp/CD38-APC and CD34-FITC/CD133/2-PE/CD45-PerCp/CD38-APC. 
Unselected BMMNC from AML patients were also incubated with the mAbs panel 
CD34-FITC/CD117-PE/CD45-PerCp/CD14-APC to test for KIT (CD117) 
expression. At the end of incubation, red blood cells were lysed for 10 minutes at 
room temperature by adding 3ml of ammonium chloride. Cells were centrifuged at 
800×g for 8 minutes, and the cell pellet was resuspended in 500 µl of PBS for flow 
cytometry analysis. All measurements were performed on a dual-laser 
FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) and contained 
10,000 to 50,000 cells, adjusted to the leukocyte subpopulations in the CD45/side 
scatter plot. Data acquisition was performed with the CellQUEST software, 
whereas both CellQUEST and Paint-a-Gate (Becton Dickinson) were used for 
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analysis. Multiparameter analysis including logical gates on forward scatter, side 
scatter, FL1, FL2, FL3, and FL4 was used to evaluate cell populations. 
4.3 Microarrays expression analysis and statistical bioinformatics analysis. 
4.3.1. Sample preparation and Affymetrix platform. 
Total RNA for expression profiling was extracted using RNAqueous®-4PCR kit. 
(Ambion) from AC133 selected cells. Expression profiling has been performed on 
Affymetrix HGU133Plus2 arrays according to the manufacturer’s procedures. The 
entire bioinformatics tests performed in this study were realized using the R 
language for statistical computing and the annotation libraries provided by the 
Bioconductor project. Thus, we removed, from our transcriptional regulator set, all 
the gene symbols lacking an annotation in the Bioconductor annotation package 
associated with the Affymetrix HGU133Plus2 platform. This step was realized by 
mean of in house written R scripts based on the Bioconductor (hgu133plus2.db 
package version 2.2.5 ). For easiness of visualization in the heatmap, in the case 
of genes represented by more than one probe set, the following procedure has 
been applied to identify a unique representative probe set for each gene: i) any 
probe set of type ‘_x_at’ associated to the gene has been removed, if at least one 
probe sets not of type ‘_x_at’ was also associated to the gene; ii) among the 
remaining probe sets, the one with the lowest P value has been chosen as 
representative for the gene. Microarray data have been deposited in ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress/), with accession number E-MTAB-220. 
4.3.2. A genome-wide approach: the functional enrichment analysis. 
In order to identify functional groups and deregulated pathways in AC133+ fraction, 
a genome-wide functional enrichment analysis was performed on AML and healthy 
donors samples. We adopt three different functional methods to reach a more 
robust identification of overrepresented regulatory networks and pathways in AML 
cells like as GOstats, DAVID and deregulated pathway analysis. GOstats selected 
terms with p-value<0.01. Among them, the “positive and negative regulation of 
WNT receptors” terms were included in both aspects of the analysis: the genome-
wide level and the TR genes restricted level. DAVID functional analysis selected 
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terms with p-value<0.05. In both analysis, the genome-wide level and the TR 
genes restricted level, the “regulation of WNT receptors signaling pathway” 
emerged. Using a non-parametric test like the deregulated pathways analysis, test 
applied by Weissman et al.112, terms were selected at p-value<0.05. After the 
analysis the “WNT receptor signaling pathway regulation” came out in all the 
analysis performed, even using KEGG. 
4.3.3. Generation of an evolutionarily conserved human transcriptional regulators 
dataset. 
The first step in our gene expression analysis consisted in the definition of a set of 
genes annotated as transcriptional regulators (TRs) and conserved in a broad 
range of organisms, from yeast to human (Figure 10 left). The entry point of our 
selection procedure was the extraction from Pfam of all the domains involved in 
transcription regulation, which resulted in a set of 400 Pfam domains. Next, we 
used this list to query the entire set of ensemble human genes using the BioMART 
web interface25. This produced an initial set of 2,971 non-redundant genes 
associated to a unique HGNC symbol. We thus adopted a direct SQL access to the 
ensembl_compara_51 database (hosted at ensembldb.ensembl.org) in order to 
extract all the one-to-one orthology relationships occurring between the genes in 
the initial set and the complete set of genes in the following organisms: Bos taurus, 
Canis familiaris, Danio rerio, Drosophila melanogaster, Equus caballus, Gallus 
gallus, Loxodonta africana, Mus musculus, Saccharomyces cerevisiae, Takifugu 
rubripes and Xenopus tropicalis. We then compiled an evolutionarily conserved set 
of TRs by arbitrarily requiring the presence of at least 5 one-to-one orthology 
relationships disregarding the involved species. This produced a set composed of 
1,989 non-redundant genes. We finally tested each of the 1,989 gene symbols 
obtained through the orthology filtering for the association with at least 1 probe set 
in the Affymetrix HGU133Plus2 array. This returned a final set of conserved 
putative transcriptional regulators composed of 1,919 genes. A procedure aimed to 
build a whole-genome set of transcription factor genes was published by Messina 
and colleagues113. The pipeline adopted by the authors resulted in the definition of 
a set of 1,468 human TFs. In order to explain the difference in size, we compared 
our pipeline with the procedure presented in Messina et al.113. After considering the 
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absence of a comparative genomics filtering in Messina et al.113, the most relevant 
difference between the compared approaches is the absence in our pipeline of a 
filtering aimed at providing strong support for the expression of our set of TRs. We 
thus check our conserved set of TRs for an overlap with annotated NCBI’s 
UniGene clusters. Again, the required annotations were obtained using the 
BioMART web interface and the whole human known Ensembl gene set (version 
51) and limiting the extraction to a set of genes produced by the orthology 1-to-1 
multi-species filter. One thousand, six hundred and twenty conserved TRs genes 
were found to overlap with at least 1 NCBI UniGene cluster. Therefore we removed 
from our set of TRs all the gene symbols lacking an annotation in the Bioconductor 
annotation package associated with the HGU133Plus2 array. This filtering 
procedure produced the reference conserved TRs set composed of 1,611 
evolutionarily conserved genes (Figure 10 right). 
 
Figure 10. Bioinformatic analysis of data derived from microarrays analysis. 
Construction of a set of conserved human transcriptional regulators (TRs) and 
differential expression analysis. The 734 differentially overexpressed genes were 
enrolled for the functional enrichment analysis. 
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4.3.4. Functional enrichment using the Bioconductor GOstats package. 
The genes comprised in the conserved TRs set were tested for differential 
expression in AC133+ AML cells. In this stage of the analysis our goal was to 
isolate a set of genes highly or moderately overexpressed in the pathological 
condition under analysis in order to identify genes suitable for ontology driven 
functional enrichment investigations basing on a standard hypergeometric test. A 
commonplace approach is to be less selective during the extraction of the 
differentially expressed gene sets and then to apply more stringent statistical 
significance cutoffs during the functional enrichment test. Following this approach 
we selected a set of overexpressed conserved TRs by means of Welch t-test 
(α=.05, one-tailed). This procedure identified a set of 734 conserved putative TRs 
overexpressed in AC133+ AML cells. The overexpressed TR genes were then 
tested for functional enrichment using the Bioconductor GOstats package (function: 
hyperGTest). As expected, all the functional terms retrieved are associated with 
regulatory processes because of the nature of the universe set, which is entirely 
composed of TRs. Among the selected functional terms the most specific one, with 
respect to the GO Biological Process ontology, is the term ‘GO:0016055’ (Figure 
11), associated with the “Wnt receptor signaling pathway” and composed of 38 
genes, 26 of which resulted significant by the Welch t-test (Supplementary Table 
2). 
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Figure 11. Gene Ontology Tree from the enrichment analysis. Enriched Gene 
Ontology Biological Process terms are plotted in light gray, the ‘Wnt Signaling 
Pathway’ (GO:0016055) term is highlighted in red. The P value associated to each 
significant term is reported along with the Gene Ontology identifier. ‘GO:0016055’ 
was the most specific one (the farthest from the root of the directed acyclic graph 
encoding the relationships between the depicted functional terms). 
 
4.4  Immunoblot 
Protein extraction was performed using cold TNTG buffer from AML patients and 
healthy donors BM cells. Protein expression was demonstrated by immunoblotting 
using standard procedures. Primary antibodies used included anti-active β-catenin 
monoclonal mouse  (anti-ABC clone 8E7, Millipore) (1:5000), anti-β-catenin 
monoclonal rabbit  (E247, Abcam) (1:5000), anti-WNT10B polyclonal rabbit (H-70, 
Santa Cruz) (1:1000), anti-WNT10B monoclonal mouse (5A7, Abcam) (1:1000), 
anti-WNT2B poluclonal rabbit (Abcam) (1:1000) anti-GAPDH polyclonal rabbit 
(ab97626, Abcam) (1:5000), anti-Pygopus 2 polyclonal rabbit (H-216, Santa Cruz 
Biotechnology, Inc.) (1:1000). Secondary antibodies used were anti-mouse-HRP, 
	   36	  
anti-goat-HRP and anti-rabbit-HRP (Thermo Scientific) (all of them at 1:10000). 
4.5  Immunofluorescence and imaging analysis 
Indirect Immunostaining was performed following standard procedures. Bone 
marrow biopsies of AML patients, previously embedded in paraffin blocks were cut 
in 5µm thick sections and mounted on slides. Slides were loaded into glass slide-
holders and dewaxed as follows: twice in 100% xylene (Carlo Erba Reagents, 
Rodano, Italy) 15min and 10min, twice in 100% EtOH (Panreac, Quimica Sau, 
Castellar del Vallès, Spain) for 5min, once in 95% EtOH for 5min, once in 85% 
EtOH for 5min, once in 65% EtOH for 5min, once in 30% EtOH for 5min and three 
times in water for 5min each. Epitope retrieval was performed using the boiling 
method with buffer Citrate (10mM, pH6). Slides were dipped into already boiling 
buffer citrate for 20min and then brought to room temperature in water. The 
blocking procedure was performed overnight using Phosphate Buffered Saline 
(PBS) plus 5% Bovine Serum Albumin (BSA) (Sigma Aldrich, St. Louis, US) and 
0.05% Tween 20 (Roche, Mannheim, Germany). The day after, slides were 
incubated with primary antibodies such as mouse anti-CD133.1 (AC133) (1:100, 
Milteny Biotech, Bergisch Gladbach, Germany), mouse anti-Active-β-Catenin 
(1:100, Millipore, Billerica, MA, US), rabbit anti-WNT10B (H70) (1:100, Santa Cruz 
Biotechnology, Santa Cruz, CA, US), rabbit anti-Pygopus 2 (H-216) (1:100, Santa 
Cruz Biotechnology), goat anti-SMYD3 (F-19) (1:100, Santa Cruz Biotechnology) 
for 5h and then washed three times with PBS plus 5% BSA and 0.05% Tween 20. 
Samples were incubated with the secondary antibodies donkey anti-mouse Alexa 
Fluor 488 (1:500, Life Technologies, Carlsband, CA, US), donkey anti-rabbit Alexa 
Fluor 568 (1:500, Life technologies) and donkey anti-goat Alexa Fluor 568 (1:500, 
Life technologies). Nuclei were counterstained with 100ng/ml DAPI (Sigma-
Aldrich). Cells were analyzed using the upright microscope (Leica, DM 4000B). 
Image analysis was performed by means of a custom automatic routine and the 
ImageJ program (1.43s NIH, USA). Maps of ABC+/WNT10B+ cells were obtained 
using an automatic threshold based on moments algorithm newly implemented in 
the ImageJ program and mathematical morphology plug-in developed by D. 
Prodanov [http://rsbweb.nih.gov/ij/plugins/gray-morphology.html]. DAPI staining 
was used to identify nuclei. Finally, images of nuclei for positive cells were obtained 
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by Boolean AND operations between DAPI staining and cell maps. The resulting 
images were used to determine the percentage of ABC+/WNT10B+ cells both 
manually or by the Analyze Particles function of ImageJ. 
4.6 Primary Cell Culture 
Selected AC133+ cells from bone marrow at diagnosis of an AML patient 
(thereafter called A46) were cultured for 16 weeks. The culture was performed 
using synthetic medium StemSpam® H3000 (StemCell Technologies), HPGM™ 
(Lonza) and X-VIVO™ 15 Medium (Lonza) in absence of serum and cytokines. 
Due to the cell number, only half volume of the total medium was replaced each 
time. The cell culture did not change phenotype using the three different media. 
StemSpan®H3000 and HPGM™ media, conditioned by the cell culture, were 
collected after 12 weeks, refined with 0.2µm filter and stored at - 20°C. HEK293T 
cells were grown following ATCC procedures. 
 
4.7  Wnt/β-Catenin responsive luciferase assay 
 
HEK293T cells grown in 24-well plates at density of 1,7 x 105 cells per well were 
transfected with M50 Super 8x TOPFlash (plasmid 12456, Addgene), containing 
eight motifs TCF/LEF for β−Catenin binding and pRL-TK (Renilla luciferase, 
Promega) using jetPEI™ (Polyplus). Cells were treated for 12h with A46 
conditioned medium (CM) or HEK293T cells transfected with BA-Wnt10b (plasmid 
1831, Addgene) CM as positive control at different doses. Wnt10b expression in 
HEK293T transfected with BA-Wnt10b was evaluated by SYBR Green based real-
time RT-PCR using Wnt10b FW-5’-GCTGTAACCATGACATGGAC-3’, and RW-5’-
CTGCCTGATGTGCCATGAC-3’ specific primers. Luciferase activity measurement 
was performed with the Dual-Luciferase Reporter Assay System (Promega). 
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4.8  Zebrafish models and transplantation procedures. 
Embryos were handled according to relevant national and international guidelines. 
Fishes of the AB strain were maintained at 28°C on a 14-hr light/10-hr dark cycle. 
Embryos were collected by natural spawning and staged according to Kimmel114. 
Zebrafish embryo cells transplantation was performed as previously reported115. 
Briefly, A46 cells concentrated at 1x104 cell/µl were incubated with Hoechst 33342 
(5µg/ml final concentration), the incubation was carried out for 2h at 37°C. 
Fluorescently labeled A46 cells were resuspended in 1x PBS and injected into 
zebrafish at 3hpf using between 100 and 200 cells each injection. Live embryos 
were observed at 70% epiboly to ensure the presence of fluorescent A46 cells. 
Embryos have been collected and fixed in 4% paraformaldehyde/PBS at 70% 
epiboly and 24 hpf, dehydrated in 100% methanol and stored at -20°C until 
processed for wholemount in-situ hybridization (WISH). WISH was carried out 
according to Thisse and colleagues116. 
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5. RESULTS 
5.1 AC133 positivity is a widespread feature of AML blast. 
 AC133 antigen is restricted to a rare cell population with long-term reconstituting 
activity, ranging from 20% to 60% of all CD34+ cells, and resulting barely 
detectable in CD34-Lin- cells. To determine the anatomical distribution of 
AC133+cells in AML, we evaluated by immunostaining a number of bone marrow 
biopsy sections from five randomly selected cases of AML patients. In all of the 
samples, cells positive for AC133 antibody were organized in little islands with 
exception for some sporadic cell. AC133 positive cells were well recognizable: they 
were smaller and iper-chromatic, in the DAPI fluorescence, respect the surrounding 
microenvironment constituted mostly by negative tumor blasts (Fig.12). 
 
 
Figure 12. Immunostained AC133 positive cells localized in chromatic islands 
in AML BM biopsy.  Representative Immunofluorescence micrographs show in 
green the cells expressing AC133 (CD133.1) and in blue, with the DAPI staining, 
the nuclei in BM section of AML#9 patient. All images were acquired with a X40 
objective. 
 
In order to establish the range of the expanded AC133+ population in AML 
samples, a flow cytometric quantification of CD133.1 expression was performed in 
single staining or in combination with the pan-hematopoietic marker CD45 on 25 
primary AML bone marrow human samples and 10 age-matched healthy volunteer 
adult donors. (Fig.13) 
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Figure 13. Flow Cytometric representation of AC133 expression in a healthy 
donor and AML#42. In the healthy donor AC133 positive cells constitute the 
0.15% of the population while in a prototypic patient the percentage can reach the 
21.0%. 
 
CD133.1 cell fraction was dramatically expanded in all the patients, for example  
AML#42 shows a 200fold difference in AC133+ cells percentage respect the 
healthy donor . The AC133+ expansion in all the AML samples averaged about 
31.5% (interquartile range (IQR): 16.5%-53.4%) compared the one in the healthy 
donors that did not reached the 1% of the expansion (median 0.54%, IQR: 0.17%-
1.14%, P<0.0001) (FIG-3), with a increase of 300 fold respect the physiologic 
expression of AC133+.  
 
Figure 14. Distribution of AC133+ expansion in AML samples and healthy 
donors. Flow cytometry analysis of the CD133.1 antigen in BM MNCs of healthy 
donors (n=10) and AML patients (n=25). 
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5.2. Identification of a common human transcriptional regulators signature in 
AC133 positive cells of AML patients. 
 
To obtain insight into the Wnt pathway in AC133+ leukemia cells, we performed a 
(re)analysis of microarray data by using all the WNT probe sets annotated to GO 
class ‘GO: 0016055’ or to any of its children GO terms. The obtained probe set list 
has been complemented with the probes mapping to genes in a manually selected 
list of WNT target genes and with probes mapping to other well-known WNT 
genes, not included in the previous two lists. The total list of analyzed WNT genes 
includes 480 probe sets, mapping to 193 different genes. To assess differential 
expression of WNT genes we employed Welch t-tests (two-tailed) on the 480 probe 
sets, thus identifying 103 differentially expressed genes (Supplementary Table 3). 
Taking into account the WNT ligands (WNT2B, WNT6, WNT10A, and WNT10B)117, 
the Wnt/β-catenin signaling agonists (including SMYD3118, DKK2119, SOX4120, 
PROP-1121, PYGO2122-123) and antagonists (including WIF-1124, KLHL12125, LRP6, 
KREMEN1126, E2F1127, DACT1128, and HBP1129), showing the lower P value as 
evaluated by the Bonferroni correction, we have built a network model covering the 
deregulated targets (including STAT3, MYCN, ABCC4130, DLX3, MARK4, 
RUNX2131, CD24132, CD44133) within the canonical Wnt/β-catenin pathway (Fig. 
15). Collectively, these data are consistent with ligand-dependent activation of the 
regeneration-associated Wnt pathway112,134. Genes that result overexpressed are 
promoting the WNT/β-catenin signaling while the one resulted underexpressed 
have an inhibitory function in the physiologic microenvironment. 
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Figure 15. Model of transcriptional regulators involved in AML pathogenesis. 
The dysregulated genes are all insert in a model of interaction. Red color 
represents up-regulation, and blue color represents down-regulation in AC133+ 
AML cells relative to normal AC133+ LT-HSCs. 
 
5.3. Activation of Wnt signaling resulted in diffuse expression of the 
hematopoietic regenerative molecule WNT10B. 
Taking into consideration our findings suggesting a transcriptional activation of 
canonical WNTs, we focused our research on the genes that have been shown to 
strongly regulate stem cells functions. First of all, we wanted to investigate the key 
molecule of the WNT canonical pathway activation:  N-terminally dephosphorylated 
β-catenin (active-β-catenin, ABC). Active-β-catenin were found largely expressed 
in AML patients in both tissues analyzed, bone marrow smear and total MNCs 
respectively, by immunostaining (Fig.16). 
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Figure 16. Expression of active β-catenin (ABC) in AML samples. The key 
molecules for WNT canonical pathway activation, the ABC are expressed in AMLs 
sample (green). In the BM of AML#1 only some cells does express ABC mainly in 
the cytoplasm. ABC are found expressed also in BM smears of AML#2 and AML#4 
patients. 
Our gene expression analysis disclosed that the entire set of canonical Wnt ligands 
activated during tissue regeneration109, including WNT2B, WNT6, WNT10A, and 
WNT10B, were among the most strongly upregulated genes in AC133+ AML cells 
(Fig.15). On this purpose, we wanted to investigate the anatomical distribution of 
cells in which WNTs canonical pathway was activated and we choose WNT10B for 
their strong association to the regenerative function.(Fig.17) 
 
Figure 17. Expression WNT10B in AML BM smear and biopsy. WNT10B is 
expressed in the BM of AML patients as a ligand, well identified in AML#70 and in 
little island of cells, identifiable for their dimension and bright DAPI staining.  
WNT10B protein was found expressed in not all the cells but in cluster of very 
chromatic cells. Double immunostaining for WNT10B and ABC, followed by ImageJ 
analysis, confirmed that WNT10B is expressed by a high proportion of leukemic 
cells, and its presence correlates with cytoplasmic accumulation of active-β-catenin 
in an estimated proportion of eight percent of cells (Fig. 18 right). WNT10B 
antibody staining was also detectable in interstitial spaces, suggesting its secretion 
and release in the bone marrow microenvironment. The slides revealed that 
WNT10B is diffusely expressed but that only a few small cells (8-10µm diameter of 
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the nuclei), with a clonal appearance and increased N:C ratio, shared the Wnt 
signaling activation signature represented by cytoplasmic accumulation of the 
active form of β-catenin21, likely induced through an autocrine/paracrine 
mechanism (Fig. 18 left), suggesting a LIGAND-depend activation of the WNT/β-
catenin pathway. 
 
Figure 18. WNT10B/β-catenin double staining in AML patients. The double 
staining for WNT10B and β-Catenin in biopsy of 5 different AML patients identifies 
the activation of the WNT signaling induced through an autocrine/paracrine 
mechanism (left) and imaging analysis highlighted that in 8% of the cell there is a 
correspondence of WNT10B and β-Catenin signals. 
 
The expression of WNT10B was confirmed in immunoblotting analysis. 
Remarkably, we found a dramatic increase in WNT10B and WNT2B expression in 
a subset of patients’ samples, except for one, reanalyzed by immunoblot (Fig.19). 
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Figure 19. WNT10B/β-Catnenin pathway is activated in AML patients.  
Immunoblot analysis of active β-catenin (ABC), β-catenin (as detected with the N-
terminal pan-β-catenin antibody), WNT10B (ab91201), Pygopus 2 proteins 
expression in AC133+ cells fractions from 18 patient’s samples and on healthy 
donor introduced as control. Interestingly, AML#40 that developed an AML 
therapy-related does not show the activation of the WNT10B/β−catenin.  
 
Interestingly, the only AML patient negative for the WNT10B expression (AML#40 
in Supplementary Table 1) was affected by therapy-related AML. We then 
decided to investigate also a downstream actor of the WNT signaling and we 
decided to study PIGO2 expression. In immunostaining PYGO2 expression in 
associated with the Active β-catenin one suggesting that the WNT activation, 
marked by ABC expression, is involving also downstream proteins like PYGO2, 
founded expressed also with immunoblot. In order to show that this phenomenon is 
spread in more than one WNT signaling ligands, associate to the regeneration 
function, we decided to investigate by immunoblot the expression of WNT2B 
(Figure 20). The same expression pattern obtained for WNT10B was recapitulated 
for the WNT2B. 
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Figure 20. WNT2B is activated in AML patients.  Immunoblot analysis for 
WNT2B protein in AML patients confirm the activation of the WNT signaling 
associated to the regeneration function in AML.  
 
5.4. WNT10B expression in AC133+ leukemic primary cell culture. 
Since now we could demonstrate the activation of the WNT signaling in human 
samples showing the expression of active β-catenin and WNTs ligands in leukemic 
tissues. In order to mimic the in-vivo state, a primary AC133+ cell culture (termed 
A46 hereafter) was established. A46 cells, with diploid karyotype, were selected 
from a 66 years old male at diagnosis of AML-M2. The immunophenotype 
characterization of the unselected cells revealed that there was a dominant 
CD133.1+CD34+CD38-CD45+CD117+ blast population (59%), that could for sure 
contribute to enrich the primary cell culture with a LIC population (Fig.21).  
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Figure 21. Dot plots of the immunophenotype analysis from AML#46 BM 
MNCs at diagnosis and after selection. Patterns of CD38/CD133.1 (top left), 
CD117/CD45 (top right), CD34/CD38 (below left) co-staining was gated on BM 
AML cells before selection. Representative CD34 and CD38 expression on 
Ficoll™-selected MNCs (below center) and AC133 sorted cells prior to culture 
(below right) is shown. Percentages on total cellularity are shown for gated AML 
populations  
 
The cells were grown in three different media, StemSpan®H3000 (Stem Cell 
Technologies), HPGM (Lonza) and X15 Vivo (Lonza). All of the three cultures were 
kept without serum or growth factors and they were carried on for 16 weeks. The 
cells, once seeded, present a heterogeneous aspect but after a couple of weeks, 
very small, translucent and round cells constituted the only homogeneous 
population of cells. The A46 cells created, in vitro, their own microenvironment and 
in order to study whether A46 were secreting WNTs compounds I collected the A46 
conditioned medium (A46-CM). To further investigate whether leukemia cells 
release WNTs in the medium and if these ligands are able to induce the β-catenin, 
A46-CM was used to evaluate β-catenin-mediated transcriptional activation. To this 
aim, HEK293T cells (H293T), transfected with Super8XTOPFlash β-catenin/TCF 
transcription-based reporter construct, were exposed either to pBA-Wnt10b H293T-
CM as control (Fig. 22 left) or A46-CM. This construct could be efficiently 
expressed in a dose-dependent manner when transiently exposed to A46-CM for 
12h (Fig. 22 right).  
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Figure 22. TOPFlash reporter assay showing luciferase expression driven by 
8 TCF/LEF binding sites. (left) Positive control was obtained by conditioned 
medium (CM) of pBA-Wnt10b-transfected H293T cells. Expression of Wnt10b was 
evaluated in pBA-Wnt10b transfected H293T by real-time PCR (left). TOPFlash 
reporter assay shows luciferase expression induced in Super8xTOPflash-H293T 
cells by pBA-Wnt10b H293T-CM (centre). (right) TOPFlash reporter assay showing 
dose-dependent luciferase expression induced in Super8xTOPflash-H293T cells 
by A46-CM. Significance was evaluated by t-test (two-tailed, α=.01). Data 
represent the mean ± s.d. of triplicate reactions and are representative of three 
independent experiments. 
 
5.5. Transplantation in zebrafish embryo of AC133+ leukemic primary cell 
culture induces ectopic axial structures formation by Wnt signaling 
activation. 
At this point, we investigated the physiological response of the WNT10B 
expression and release effect in a developmental model; to this aim we decided to 
use the zebrafish as a biosensor to investigate possible tumor-derived signals after 
A46 transplantation. Wnt pathway is among the most evolutionarily conserved 
signalings, and has been strongly implicated in body axis formation. Patterning of 
zebrafish body plan requires the activity of the factors bozozok (boz) and squint 
(sqt) that trigger the expression of the organizer/mesoderm marker goosecoid 
(gsc), among others48. We hypothesized that A46 cells, transplanted into 
developing zebrafish embryos, can induce the formation of additional axial 
structures following on activation of markers that are normally dependent on the 
Wnt pathway. Thus, we injected Hoechst 33342 fluorescently labeled A46 and 
normal bone marrow-derived AC133+ cells (control) into zebrafish embryos at 3hpf 
stage (Fig. 23a), and the effects on the expression pattern of gsc at the 70% 
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epiboly stage have been analyzed (Fig. 23b-d). While normal AC133+ cells did not 
alter the normal expression of the gene (Fig. 23b), 29% of the embryos grafted 
with A46 cells (n=208) displayed both the expansion of the gsc endogenous 
domain and its ectopic activation in the dorsal and ventral aspects of the animal 
pole (Fig. 23c,d). 
 
Figure 23. A46 AML cells induce ectopic gene zebrafish embryos. (a) 
Fluorescence microscopy of a live zebrafish embryo transplanted at 3hpf with A46 
cells previously blue-stained with Hoechst 33342. (b-d) Animal pole view of 70% 
epiboly-stage embryos hybridized with a gsc-specific probe. Embryos have been 
injected at the blastula stage with (b) normal AC133+ cells as control or (c) A46 
AML cells. The gsc-ectopic signals in the embryos injected with A46 are highlighted 
in (d). 
 
According to the ectopic expression of this organizer marker, the embryos injected 
with A46 cells developed secondary structures, ranging from the formation of 
additional non-axial tail tissues (Fig. 24e-g), to the emergence of extra axial (Fig. 
24h) or head structures (Fig. 24i). Most of the embryos displayed dramatic early 
development defects and lethality at 10 hours post fertilization (hpf). 
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Figure 24. A46 AML cells induce secondary body axes formation in zebrafish 
embryos. The embryo in (E) has been hybridized with a probe specific for the 
mesodermal marker ntl. (F) The probe labels the notochord (n) in the endogenous 
trunk and the chordoneural hinge (cnh) in both tails (G, higher magnification). (H) 
Tail of a 24hpf embryo hybridized with ntl-specific probe. The endogenous (n) and 
ectopic (*n) ntl signals run parallel along the axis of the embryo, indicating the 
presence of additional axial structures. (I) Dorsal view of a 24hpf embryo that 
developed an ectopic head on the side of the endogenous one, as indicated by the 
expression of the brain-marker gene pax2a. The dotted lines indicate the main (M) 
and secondary (S) axes. The optic stalk (OS) in close vicinity to the eye (e), the 
midbrain-hindbrain boundary (MHB), and the otic vesicles (OV) of the embryo are 
stained with the pax2a riboprobe, as well as several areas of the ectopic head (the 
asterisks indicate the two clearly recognizable additional otic vesicles). The image 
is composed of different pictures corresponding to several focal planes, since the 
embryo is not flat, and a single focal plane cannot comprise all the labeled 
structures belonging to the main and secondary axes. Scale bars represent 125 
mm (a,b,c,d), 150 mm (e), 40 mm (f), 15 mm (g,i), or 25 mm (h). 
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6. DISCUSSION 
A fundamental challenge in cancer research is the identification of cells within a 
tumor that sustain the growth of the neoplastic clone. Phenotypic evidence 
indicates that somatic stem cells are target cells for malignant transformation135. 
The human AML-initiating cell, defined as SCID leukemia-initiating cell (SL-IC), 
was identified and purified by transplantation into NOD/SCID mice that 
recapitulates the human disease136. Based on these findings, it has been proposed 
a hierarchical organization for AML that is similar to normal hematopoiesis, in 
which the LSC is responsible for both self-renewal and the production of 
clonogenic leukemic progenitors that have proliferative capacity, but not the 
capacity of self-renewal. In this scenario the HSC is the most likely target for 
transformation into a LSC77,137. The concept that leukemia-initiating cell (LIC) 
properties occur in a self-renewing non-HSC progenitor cell population, preceded 
by the expansion of a preleukemic long-term hematopoietic stem cell (LT-HSC), 
has been recently reinforced138-140. However, the molecular function responsible for 
the preleukemic LT-HSC expansion and the acquisition of self-renewal ability in 
AML remain poorly defined. Human HSCs have traditionally been characterized by 
the expression of cell surface markers such as CD34, but not all human 
hematopoietic repopulating cells express CD34141. AC133 represents a 
glycosylation-dependent epitope of CD133 and its expression is restricted to a 
blood cell population highly enriched in HSCs CD34high, CD38low, c-Kit+89. This 
protein is thus one of the most specific markers for HSCs currently available. 
Furthermore, AC133+/CD34+ cells have a higher clonogenic capacity and 
engraftment rate than AC133-/CD34+ cells92. For the first time, here we show that 
AC133+ cells are highly expanded in AML by an average of 31.5% respect to 
healthy donors. In all the analyzed samples the AC133 immunostaining revealed 
clusters of positive cells, or single positive cells, amid a majority of negative tumor 
blasts. Some on the AC133+ clusters distribute in a symmetric manner, suggesting 
a possible clonal origin. Results achieved by a genome wide and multistep analysis 
of the generated data from microarray analysis defined the involvement of the 
distinct Wnt signaling pathway associated to the regeneration of HSCs as the 
master deregulated function in AC133-enriched fraction in human AML. Recently, 
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Wnt/β-catenin pathway requirement for LIC development in AML has emerged in a 
mouse model142. The results presented here provide direct evidence that the 
Wnt/β-catenin signaling is diffusely activated in human AC133+ AML cells in a 
ligand dependent manner, with a specific transcriptional signature involving 
overexpression of the Wnt pathway agonists and down-modulation of the major 
antagonists. Notably, WNT2B, WNT6, WNT10A, and WNT10B, known to promote 
tissue regeneration117,143,144, are the WNT mediators specifically upregulated in the 
AC133+ AML cells. Consistent with the latter observation, we found also a 
dramatic increase of WNT10B and WNT2B expression in the large majority of 
samples from AML patients recruited to this study, with the exception of the unique 
therapy-related AML patient, thus suggesting an etiology-dependent deregulation. 
For the first time we could see the anatomic distribution of the leukemic cells in the 
BM of AML patients via the immunoblotting performed on BM biopsies. 
Nevertheless, exclusively we show a massive WNT10B expression in certain cells 
concomitantly with the diffuse release in the leukemic microenvironment of AML 
patients suggesting a ligand-dependent activation mode of the Wnt/β-catenin. In 
accordance with previous studies145, we have not detected WNT10B gene 
expression in normal marrow hematopoietic cells, however WNT10B was found in 
the microenvironment that supports B cell differentiation146. In addition, there is 
evidence that in the hematopoietic system WNT10B and WNT10B is specifically 
and significantly upregulated following an injury, and that WNT10B acts to enhance 
the growth of HSCs144. It is also worth noting that grater fold expansion of murine 
hematopoietic stem cell progenitors was obtained after WNT10B conditioned 
media exposure145. Another ligand directly related to the regeneration function is 
WNT2B that we found massively expressed in AML patients except for the therapy 
related one, suggesting that the main “characters” of the regeneration function are 
implicated in leukemia initiation. Considering PYGO2 key role in promoting Wnt 
ligands responsiveness through its ability to interact with trimethylated K4 residues 
of histone H3 and its interaction with BCL9-β-catenin complexes at Wnt target 
genes122-123, the shared overexpression of PYGO2 here documented in AML was 
not surprising. The establishment of a primary leukemic cell culture from AC133+ 
cells of an AML patient let us consider that this fraction was effectively enriched for 
the LIC since it lasted for 16 weeks without being treated with cytokines or serum. 
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Moreover, we are able to demonstrate that leukemia cells release WNTs ligands in 
the microenvironment conditioning the culture medium. Interestingly, the WNTs 
released in the medium are able to induce β-catenin activation in a dose 
dependent manner. It also is well known the pivotal role of WNTs gradients and 
β−catenin stabilization in establishing the dorsal organizer in zebrafish embryos147. 
Here we have demonstrated that cultured AC133+ A46 cells have the ability to 
cause secondary ectopic organizers marked by the Wnt/β−catenin dependent 
marker gsc. Finally, A46 cells are able to induce a secondary axis formation in 
zebrafish	   embryos through the initiation of dorsal or tail organizer activity148 by 
inducing Wnt dependent markers. 
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7. CONCLUSIONS 
A new and pivotal insight for cancer research is the identification of cells within a 
tumor that sustain the growth of neoplastic clone. The entire cellular diversity of 
AML was recapitulated establishing that leukemia is organized as a hierarchy 
sustained by rare leukemia stem cells (LSCs) resembling normal development, 
although LSCs possess higher self-renewal capacity. AC133 is one of the most 
specific and efficient cell surface marker available for the hematopoietic stem cell. 
Here we show that AC133+ population in AML patients is highly expressed 
compared to the healthy donor cells AC133+. In the bone marrow of AML patients, 
AC133+ distribute in clustered population surrounded by blasts, in a simil-
symmetric disposition suggesting a clonal origin. For the first time, here we show 
the anatomical disposition of AC133+ cells in AML patients. The AC133+ fractions 
were employed to gene expression microarray analysis, gene-ontology-based 
functional annotations and bioinformatic tools in order to study the leukemogenesis 
focusing on transcriptional regulators as mediators of reprogramming. From the  
functional enrichment analysis, obtained using GOstats Bioconductor package, a 
pivotal and unique transcriptional pathway has emerged: the wnt receptor signaling 
pathway. Here we propose an interaction model in which defined master “executer” 
TR in synergism with chromatin re-modellers enhance the responsiveness of the 
system acting to induce a stronger, possibly leukemogenic, response of the final 
“player” genes. Thus, in vitro experiments performed on AML patients samples 
allowed us to demonstrated the massive activation of WNT/β−catenin signaling 
pathway in a ligand depend way, for example via an expression 
autocrine/paracrine of WNT10B, one of the principal ligand belonging to the WNT 
signaling that is strongly associated to the regenerative function. Also WNT2B, a 
second and not less important actor of the regeneration function, is highly activated 
in AML patients except for the only therapy-related one. Finally, AC133+ A46 
leukemic primary culture is able to release in the medium WNTs that can induce β-
catenin activation in a dose dependent manner. Thus AC133+A46 cell showed a 
regenerative potential inducing the formation of secondary axial structures in 
embryos zebrafish. In light of the long-known association between cancer and 
chronic tissue injury107, and because of the higher homeostatic range of Wnt/β-
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catenin signaling occurring during regeneration upon an acute injury120. Our data 
rise important implications for the involvement of the Wnt pathway in the origin of 
AML, considering its pivotal function in promoting self-renewal22, its emerging role 
in myeloid leukemogenesis137, and the effects of its constitutive activation via a 
stabilized form of β-catenin, a key component of canonical Wnt signalling137, by 
inducing quiescent stem cells to enter the cell cycle and by arresting their 
differentiation. 
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Supplementary Table 1. Clinical characteristics and outcome of AML patients 
 
No Age,y/ sex FAB Cytogenetics* FLT3 NPM1 
WBC, 
x 109/L 
MO blast, 
% EML s-AML 
Response 
to 
induction 
Relapse Outcome 
#1 67/M M2 45,XY,-7 wt - 1,7 55 Absent Yes° CR Yes D/1st res rel 
#2 45/M M1 Complex karyotype wt - 1,7 60 Absent No PR No A/1st CR 
#4 59/M M4 46,XY,del(20)(q11q13) wt - 3,5 32 Absent No ref dis No A/1st CR 
#5 47/F M4 46,XX ITD - 84,6 80 Skin No CR No A/1st CR 
#6 76/F M4 47,XX,+11 wt - -  Absent Yes° Ref dis n.a. D/prim ref dis 
#9 20/M M0 46,XY wt - 3,6 80 Absent No CR Yes A/2nd CR 
#10 62/F M5a 46,XX wt - 69 90 Skin No ref dis No A/1st CR 
#13 57/M M1 46,XY,t(6;9)(p23;q34) ITD wt 39,7 89 Absent No ref dis n.a. D/prim ref dis 
#14 72/F M2 46,XX wt - -  Absent No ref dis n.a. D/prim ref dis 
#16 41/F M2 46,XX wt wt 15,9 45 Absent No CR No A/1st CR 
#17 29/M M1 46,XY ITD wt 217,7 96 Absent No CR Yes D/1st res rel 
#19 29/F M1 46,XX,del(11q23) wt - 110,6 95 Skin No ref dis Yes D/1st res rel 
#21 22/M M1 46,XY ITD wt 16,7 75 Absent No ref dis No A/1st CR 
#23 65/M M1 46,XY wt wt 12,7 78 Absent No CR Yes A/2nd CR 
#24 59/M M1 46,XY wt Exon 12 20,1 75 Absent No CR Yes A/1st rel 
#25 39/F M1 46,XX,del(11q23) wt wt 15,7  Absent No ref dis n.a. D/prim ref dis 
#30 41/M M5a 46,XY wt wt 3,6 75 Absent No CR Yes A/1st rel 
#32 52/F M2 46,XX wt wt 2,7 55 Absent Yes° CR No D/TRM 1st CR 
#34 29/M M0 46,XY,del(11)(q13q23) wt wt 4 86 Absent No CR Yes D/1st res rel 
#38 59/F M1 46,XX wt Exon 12 1 82 Absent No CR Yes D/1st res rel 
#39 51/M n.a. Complex karyotype wt wt 1,2  Absent No ref dis n.a. D/prim ref dis 
#40 55/F M2 Complex karyotype wt wt 0,8 20 Absent Yes† n.a. n.a. A/active dis 
#41 62/F M4 46,XX wt wt 17 30 Skin Yes° ref dis Yes A/1st res rel 
#42 65/F M4 46,XX wt wt 1,2 60 Adnexal mass No ref dis n.a. A/prim ref dis 
#44 56/F M2 46,XX,t(8;21)(q22;q22),inv(9)(p11q12) wt wt 8,6 65 Absent No PR Yes A/2nd rel 
#46 66/M M2 46,XY ITD wt 26,8 80 Absent No PR n.a. A/prim ref dis 
#47 62/F M2 47,XX,+21 wt Exon 12 23 12 Absent Yes° n.a. n.a. A/active dis 
#48 43/M M5a 46,XY ITD Exon 12 63,9 85 Absent No CR Yes A/2nd CR 
#49 68/F biphen. 45,XX,-7,t(9;22)(q34;q11) wt wt 8,1 70 Absent No CR Yes A/2nd CR 
#50 61/F M4 Complex karyotype wt wt 8,8 35 Absent No ref dis n.a. D/prim ref dis 
#51 15/F M5b 46,XX wt wt 118 84 CNS No ref dis Yes D/1st res rel 
#52 33/M M2 46,XY wt Exon 12 20,9 40 Absent No CR No A/1st CR 
#53 51/F M1 46,XX wt Exon 12 81,1 77 Absent No CR No A/1st CR 
• A, alive; CR, complete remission;PR, partially remission;D, dead; ref dis, refratory disease; res rel, resistant relapse; biphen., biphenotypic; TRM, transplant related mortality; s-AML, secondary AML; n.a., not applicable; EML, 
extramedullary leukemia. 
• *: at diagnosis 
• °: myelodisplastic-AML 
• †: therapy-related AML 
Supplementary Table 2: Functional enrichment analysis: selected genes associated with 
GO:0016055 term. 
 
 
Gene ID Gene Gene Description 
56033 BARX1 BARX homeobox 1 
8945 BTRC beta-transducin repeat containing 
1499 CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 
1500 CTNND1 catenin (cadherin-associated protein), delta 1 
23291 FBXW11 F-box and WD repeat domain containing 11 
26959 HBP1 HMG-box transcription factor 1 
51176 LEF1 lymphoid enhancer-binding factor 1 
5626 PROP1 PROP paired-like homeobox 1 
26108 PYGO1 pygopus homolog 1 (Drosophila) 
90780 PYGO2 pygopus homolog 2 (Drosophila) 
5916 RARG retinoic acid receptor, gamma 
6657 SOX2 SRY (sex determining region Y)-box 2 
83439 TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) 
7088 TLE1 transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) 
7090 TLE3 transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) 
7091 TLE4 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 
8840 WISP1 WNT1 inducible signaling pathway protein 1 
80326 WNT10A wingless-type MMTV integration site family, member 10A 
7480 WNT10B wingless-type MMTV integration site family, member 10B 
7482 WNT2B wingless-type MMTV integration site family, member 2B 
7473 WNT3 wingless-type MMTV integration site family, member 3 
54361 WNT4 wingless-type MMTV integration site family, member 4 
81029 WNT5B wingless-type MMTV integration site family, member 5B 
7475 WNT6 wingless-type MMTV integration site family, member 6 
7479 WNT8B wingless-type MMTV integration site family, member 8B 
10009 ZBTB33 zinc finger and BTB domain containing 33 
Supplementary Table 3: “Wnt signaling” differentially expressed genes. 
 
 
a. Differentially over-expressed genes. 
Probe Gene GeneID pValue 
217729_s_at AES 166 0 
217174_s_at APC2 10297 0.011 
219845_at BARX1 56033 0.016 
211518_s_at BMP4 652 0.047 
222374_at BTRC 8945 0.041 
209002_s_at CALCOCO1 57658 0.009 
208711_s_at CCND1 595 0.034 
204490_s_at CD44 960 0 
207144_s_at CITED1 4435 0.004 
202790_at CLDN7 1366 0.014 
226920_at CSNK1A1 1452 0 
229212_at CSNK2A1 1457 0.011 
201390_s_at CSNK2B 1460 0.037 
201533_at CTNNB1 1499 0.004 
1557944_s_at CTNND1 1500 0.002 
219908_at DKK2 27123 0.009 
231778_at DLX3 1747 0.002 
38707_r_at E2F4 1874 0.004 
209589_s_at EPHB2 2048 0.005 
1438_at EPHB3 2049 0.005 
209456_s_at FBXW11 23291 0.022 
214702_at FN1 2335 0.001 
207345_at FST 10468 0.025 
224337_s_at FZD4 8322 0.004 
224325_at FZD8 8325 0.001 
218468_s_at GREM1 26585 0.016 
1552338_at GSC 145258 0.03 
209945_s_at GSK3B 2932 0.027 
205718_at ITGB7 3695 0.002 
209097_s_at JAG1 182 0.025 
204584_at L1CAM 3897 0.001 
221560_at MARK4 57787 0 
1566677_at MMP2 4313 0.004 
220541_at MMP26 56547 0.002 
204259_at MMP7 4316 0 
209756_s_at MYCN 4613 0 
206022_at NDP 4693 0.005 
229481_at NKD1 85407 0.002 
232201_at NKD2 85409 0.014 
241911_at PPP2CA 5515 0.002 
211223_at PROP1 5626 0.002 
215517_at PYGO1 26108 0.011 
225370_at PYGO2 90780 0 
2041898_at RARG 5916 0.013 
1554012_at RSPO2 340419 0.017 
221283_at RUNX2 860 0.001 
223121_s_at SFRP2 6423 0.026 
204051_s_at SFRP4 6424 0.003 
218788_s_at SMYD3 64754 0 
213456_at SOSTDC1 25928 0.003 
230943_at SOX17 64321 0.034 
1567906_at SOX4 6659 0 
208992_s_at STAT3 6774 0.007 
221016_s_at TCF7L1 83439 0.005 
227130_s_at TLE1 7088 0.013 
 
 
b. Differentially under-expressed genes. 
 
 
 
 
 
 
 
 
1553813_s_at TLE6 79816 0.001 
211312_s_at WISP1 8840 0.027 
229154_at WNT10A 80326 0.005 
206213_at WNT10B 7480 0.017 
206458_s_at WNT2B 7482 0.012 
222086_s_at WNT6 7475 0.005 
214631_at ZBTB33 10009 0.004 
Probe Gene GeneID pValue 
208161_s_at ABCC3 8714 0.008 
203196_at ABCC4 10257 0 
204129_at BCL9 607 0.018 
202094_at BIRC5 332 0.017 
238545_at BRD7 29117 0.005 
231288_at CCDC88C 440193 0.019 
266_s_at CD24 100133941 0 
201131_s_at CDH1 999 0.007 
202160_at CREBBP 1387 0.011 
219179_at DACT1 51339 0 
20198_at DVL3 1857 0.001 
204947_at E2F1 1869 0 
213579_s_at EP300 2033 0.016 
202894_at EPHB4 2050 0 
209189_at FOS 2353 0 
204451_at FZD1 8321 0 
219683_at FZD3 7976 0.017 
221245_s_at FZD5 7855 0.003 
203987_at FZD6 8323 0.004 
203705_s_at FZD7 8324 0.001 
236645_at HBP1 26959 0.001 
213931_at ID2 3398 0.002 
211055_at INVS 27130 0.004 
201465_s_at JUN 3725 0.003 
225068_at KLHL12 59349 0 
227250_at KREMEN1 83999 0.014 
221558_s_at LEF1 51176 0.011 
225745_at LRP6 4040 0 
211675_s_at MDFIC 29969 0.027 
203936_s_at MMP9 4318 0 
220184_at NANOG 79923 0.042 
229027_at PPM1A 5494 0.004 
203554_x_at PTTG1 9232 0.043 
204535_s_at REST 5978 0.037 
216645_at TCF3 6929 0.002 
212382_at TCF4 6925 0.001 
205255_x_at TCF7 6932 0.035 
212761_at TCF7L2 6934 0.005 
213135_at TIAM1 7074 0 
210512_s_at VEGFA 7422 0.005 
204712_at WIF1 11197 0 
